This O
study O
reviews O
the O
current O
proposed O
mechanisms O
of O
sudden O
death O
after O
a O
high O
dose O
of O
intravenous O
methylprednisolone O
( O
IVMP B
) O
. O

Maximal O
platelet O
aggregation O
induced O
by O
6 O
microM O
of O
adenosine B
diphosphate I
decreased O
after O
administration O
of O
ketoprofen O
. O

Tail O
blood O
pressure O
, O
urinary O
NOx O
excretion O
, O
plasma O
malondialdehyde O
( O
MDA B
) O
, O
and O
endothelial O
and O
inducible O
NOS O
( O
eNOS O
and O
iNOS O
) O
isotypes O
in O
the O
aorta O
and O
kidney O
were O
measured O
. O

The O
lead O
- O
treated O
group O
exhibited O
a O
rise O
in O
blood O
pressure O
and O
plasma O
MDA B
concentration O
, O
a O
fall O
in O
urinary O
NOx O
excretion O
, O
and O
a O
paradoxical O
rise O
in O
vascular O
and O
renal O
tissue O
eNOS O
and O
iNOS O
expression O
. O

Vitamin O
E O
supplementation O
ameliorated O
hypertension O
, O
lowered O
plasma O
MDA B
concentration O
, O
and O
raised O
urinary O
NOx O
excretion O
while O
significantly O
lowering O
vascular O
, O
but O
not O
renal O
, O
tissue O
eNOS O
and O
iNOS O
expression O
. O

Vitamin O
E O
supplementation O
had O
no O
effect O
on O
either O
blood O
pressure O
, O
plasma O
MDA B
, O
or O
NOS O
expression O
in O
the O
control O
group O
. O

Glyceryl B
trinitrate I
induces O
attacks O
of O
migraine O
without O
aura O
in O
sufferers O
of O
migraine O
with O
aura O
. O

In O
order O
to O
clarify O
whether O
the O
same O
is O
true O
for O
migraine O
with O
aura O
, O
in O
the O
present O
study O
we O
examined O
the O
headache O
response O
to O
intravenous O
infusion O
of O
glyceryl B
trinitrate I
( O
GTN B
) O
( O
0 O
. O
5 O
microg O
/ O
kg O
/ O
min O
for O
20 O
min O
) O
in O
12 O
sufferers O
of O
migraine O
with O
aura O
. O

Headache O
was O
more O
severe O
in O
migraineurs O
than O
in O
the O
controls O
during O
and O
immediately O
after O
GTN B
infusion O
( O
p O
= O
0 O
. O
037 O
) O
as O
well O
as O
during O
the O
following O
11 O
h O
( O
p O
= O
0 O
. O
008 O
) O
. O

In O
the O
controls O
, O
the O
GTN B
- O
induced O
headache O
gradually O
disappeared O
, O
whereas O
in O
migraineurs O
peak O
headache O
intensity O
occurred O
at O
a O
mean O
time O
of O
240 O
min O
post O
- O
infusion O
. O

Cyclophosphamide O
( O
CP B
) O
, O
an O
antitumoral O
agent O
known O
to O
produce O
toxic O
effects O
on O
the O
bladder O
wall O
through O
its O
main O
toxic O
metabolite O
acrolein O
, O
was O
used O
to O
induce O
cystitis O
. O

MATERIALS O
AND O
METHODS O
: O
CP B
was O
administered O
at O
doses O
of O
50 O
, O
100 O
and O
200 O
mg O
. O
/ O
kg O
. O

The O
effects O
of O
morphine O
( O
0 O
. O
5 O
to O
4 O
mg O
. O
/ O
kg O
. O
i O
. O
v O
. O
) O
on O
CP B
- O
induced O
behavioral O
modifications O
were O
tested O
administered O
alone O
and O
after O
naloxone O
( O
1 O
mg O
. O
/ O
kg O
. O
s O
. O
c O
. O
) O
. O

In O
addition O
, O
90 O
minutes O
after O
CP B
injection O
, O
that O
is O
, O
at O
the O
time O
of O
administration O
of O
morphine O
, O
the O
bladder O
was O
removed O
in O
some O
rats O
for O
histological O
examination O
. O

Finally O
, O
to O
show O
that O
the O
bladder O
is O
essential O
for O
the O
CP B
- O
induced O
behavioral O
modifications O
, O
female O
rats O
also O
received O
CP B
at O
doses O
of O
200 O
mg O
. O
/ O
kg O
. O

i O
. O
v O
. O
RESULTS O
: O
CP B
dose O
- O
relatedly O
induced O
marked O
behavioral O
modifications O
in O
male O
rats O
: O
breathing O
rate O
decrease O
, O
closing O
of O
the O
eyes O
and O
occurrence O
of O
specific O
postures O
. O

A O
dose O
of O
0 O
. O
5 O
mg O
. O
/ O
kg O
. O
produced O
a O
reduction O
of O
almost O
50 O
% O
of O
the O
behavioral O
score O
induced O
by O
CP B
200 O
mg O
. O
/ O
kg O
. O

In O
female O
rats O
, O
CP B
200 O
mg O
. O
/ O
kg O
. O

Administered O
at O
the O
dose O
of O
20 O
mg O
. O
intravesically O
, O
CP B
did O
not O
produce O
any O
behavioral O
effects O
, O
whereas O
acrolein O
at O
0 O
. O
5 O
mg O
. O
intravesically O
induced O
behavioral O
modifications O
identical O
to O
those O
under O
CP B
200 O
mg O
. O
/ O
kg O
. O

CONCLUSIONS O
: O
Overall O
, O
these O
results O
indicate O
that O
this O
experimental O
model O
of O
CP B
- O
induced O
cystitis O
may O
be O
an O
interesting O
new O
behavioral O
model O
of O
inflammatory O
visceral O
pain O
, O
allowing O
a O
better O
understanding O
of O
these O
painful O
syndromes O
and O
thus O
a O
better O
therapeutic O
approach O
to O
them O
. O

In O
the O
NASCIS O
, O
there O
was O
no O
mention O
regarding O
the O
possibility O
of O
acute O
corticosteroid B
myopathy O
that O
high O
- O
dose O
methylprednisolone O
may O
cause O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
discussion O
considering O
the O
possibility O
that O
the O
methylprednisolone O
recommended O
by O
NASCIS O
may O
cause O
acute O
corticosteroid B
myopathy O
. O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
effects O
of O
RAPA B
conversion O
in O
patients O
undergoing O
cyclosporine O
( O
CsA O
) O
or O
tacrolimus O
( O
Tac O
) O
toxicity O
. O

METHODS O
: O
Twenty O
renal O
transplant O
recipients O
were O
switched O
to O
fixed O
dose O
rapamycin O
( O
RAPA B
) O
( O
5 O
mg O
/ O
day O
) O
0 O
to O
204 O
months O
posttransplant O
. O

RAPA B
was O
discontinued O
in O
four O
patients O
, O
because O
of O
pneumonia O
in O
two O
, O
PTLD O
in O
one O
, O
and O
oral O
aphtous O
ulcers O
in O
one O
. O

RAPA B
levels O
were O
high O
( O
> O
15 O
ng O
/ O
ml O
) O
in O
7 O
of O
13 O
( O
54 O
% O
) O
patients O
. O

CONCLUSIONS O
: O
RAPA B
conversion O
provides O
adequate O
immunosuppression O
to O
enable O
CsA O
withdrawal O
. O

However O
, O
when O
converting O
patients O
to O
RAPA B
drug O
levels O
should O
be O
monitored O
to O
avoid O
over O
- O
immunosuppression O
and O
adequate O
antiviral O
and O
Pneumocystis O
carinii O
pneumonia O
prophylaxis O
should O
be O
given O
. O

STUDY O
OBJECTIVE O
: O
To O
determine O
the O
effect O
of O
metoprolol O
on O
dobutamine O
stress O
testing O
with O
technetium B
- I
99m I
sestamibi I
single O
- O
photon O
emission O
computed O
tomography O
imaging O
and O
ST O
- O
segment O
monitoring O
, O
and O
to O
assess O
the O
impact O
of O
intravenous O
glucagon O
on O
metoprolol O
' O
s O
effects O
. O

Sodium B
thiopenthal I
was O
administered O
intraperitoneally O
into O
male O
rats O
pre O
- O
treated O
with O
melatonin O
( O
0 O
. O
05 O
, O
0 O
. O
5 O
, O
5 O
and O
50 O
mg O
/ O
kg O
) O
. O

PURPOSE O
: O
To O
determine O
whether O
Myocet B
( O
liposome O
- O
encapsulated O
doxorubicin O
; O
The O
Liposome O
Company O
, O
Elan O
Corporation O
, O
Princeton O
, O
NJ O
) O
in O
combination O
with O
cyclophosphamide O
significantly O
reduces O
doxorubicin O
cardiotoxicity O
while O
providing O
comparable O
antitumor O
efficacy O
in O
first O
- O
line O
treatment O
of O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

PATIENTS O
AND O
METHODS O
: O
Two O
hundred O
ninety O
- O
seven O
patients O
with O
MBC O
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomized O
to O
receive O
either O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
Myocet B
( O
M O
) O
or O
conventional O
doxorubicin O
( O
A O
) O
, O
in O
combination O
with O
600 O
mg O
/ O
m O
( O
2 O
) O
of O
cyclophosphamide O
( O
C O
) O
, O
every O
3 O
weeks O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

CONCLUSION O
: O
Myocet B
improves O
the O
therapeutic O
index O
of O
doxorubicin O
by O
significantly O
reducing O
cardiotoxicity O
and O
grade O
4 O
neutropenia O
and O
provides O
comparable O
antitumor O
efficacy O
, O
when O
used O
in O
combination O
with O
cyclophosphamide O
as O
first O
- O
line O
therapy O
for O
MBC O
. O

The O
effects O
of O
N B
- I
nitro I
- I
L I
- I
arginine I
- I
methyl I
ester I
( O
L O
- O
NAME O
) O
a O
nitric O
oxide O
( O
NO O
) O
synthase O
inhibitor O
and O
L O
- O
arginine O
, O
a O
NO O
precursor O
, O
were O
investigated O
on O
lidocaine O
- O
induced O
convulsions O
. O

In O
the O
present O
study O
we O
aimed O
to O
investigate O
plasma O
levels O
of O
CGRP O
during O
headache O
induced O
by O
the O
NO O
donor O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
16 O
patients O
with O
chronic O
tension O
- O
type O
headache O
and O
16 O
healthy O
controls O
. O

The O
subjects O
were O
randomly O
allocated O
to O
receive O
0 O
. O
5 O
microg O
/ O
kg O
/ O
min O
GTN B
or O
placebo O
over O
20 O
min O
on O
two O
headache O
- O
free O
days O
. O

Both O
patients O
and O
controls O
developed O
significantly O
stronger O
immediate O
headache O
on O
the O
GTN B
day O
than O
on O
the O
placebo O
day O
and O
the O
headache O
was O
significantly O
more O
pronounced O
in O
patients O
than O
in O
controls O
. O

There O
was O
no O
difference O
between O
the O
area O
under O
the O
CGRP O
curve O
( O
AUCCGRP O
) O
on O
GTN B
vs O
. O
placebo O
day O
in O
either O
patients O
( O
P O
= O
0 O
. O
65 O
) O
or O
controls O
( O
P O
= O
0 O
. O
48 O
) O
. O

The O
AUCCGRP O
recorded O
on O
the O
GTN B
day O
did O
not O
differ O
between O
patients O
and O
controls O
( O
P O
= O
0 O
. O
36 O
) O
. O

Both O
in O
patients O
and O
controls O
, O
CGRP O
levels O
changed O
significantly O
over O
time O
, O
on O
both O
the O
GTN B
and O
placebo O
days O
( O
P O
< O
0 O
. O
05 O
) O
. O

Usually O
it O
is O
a O
self O
- O
limited O
disorder O
, O
but O
corticosteroid B
therapy O
may O
be O
needed O
in O
life O
- O
threatening O
cases O
since O
early O
treatment O
with O
corticosteroids O
in O
severe O
cases O
can O
prevent O
complications O
. O

Despite O
administration O
of O
phenytoin O
and O
lorazepam O
, O
the O
seizures O
persisted O
and O
occurred O
only O
during O
amphotercin B
B I
administration O
. O

No O
other O
medications O
were O
involved O
except O
for O
dipyrone B
for O
analgesia O
. O

Accidental O
reexposure O
by O
the O
patient O
to O
dipyrone B
was O
uneventful O
. O

This O
patient O
also O
developed O
torsade O
de O
pointes O
when O
cisapride O
and O
erythromycin B
were O
given O
simultaneously O
. O

We O
compared O
these O
results O
with O
those O
previously O
obtained O
with O
kainic O
acid O
( O
KA B
) O
, O
a O
potent O
glutamate O
agonist O
. O

However O
, O
pilocarpine O
- O
induced O
seizures O
result O
in O
a O
more O
widespread O
neuronal O
death O
in O
both O
WT O
and O
D2R O
- O
/ O
- O
brains O
in O
comparison O
to O
KA B
. O

Reserpine O
( O
1 O
mg O
/ O
kg O
) O
, O
administered O
90 O
min O
before O
the O
test O
and O
followed O
by O
apomophine B
injection O
( O
0 O
. O
1 O
mg O
/ O
kg O
) O
5 O
min O
before O
the O
test O
, O
did O
not O
produce O
oral O
dyskinesia O
in O
mice O
. O

Unfractionated B
heparin I
( O
UH B
) O
is O
currently O
the O
substitute O
for O
selected O
patients O
. O

Low O
- O
molecular O
- O
weight O
heparin O
( O
LMWH O
) O
offers O
theoretical O
advantages O
over O
UH B
, O
but O
is O
not O
currently O
considered O
in O
clinical O
guidelines O
as O
an O
alternative O
to O
UH B
in O
patients O
with O
prosthetic O
valves O
. O

CONCLUSIONS O
: O
In O
patients O
with O
mechanical O
heart O
valves O
, O
short O
- O
term O
LMWH O
therapy O
compares O
favorably O
with O
UH B
. O

Anesthesia O
was O
induced O
with O
5 O
mg O
. O
kg O
( O
- O
1 O
) O
thiopental B
iv O
. O
followed O
by O
succinylcholine O
( O
Group O
PS O
, O
LS O
) O
or O
rocuronium O
( O
Group O
PR O
) O
for O
tracheal O
intubation O
. O

Case O
report O
: O
Dexatrim B
( O
Phenylpropanolamine O
) O
as O
a O
cause O
of O
myocardial O
infarction O
. O

We O
report O
here O
the O
first O
case O
of O
Dexatrim B
( O
PPA O
) O
- O
induced O
myocardial O
injury O
in O
a O
young O
woman O
who O
was O
using O
it O
at O
recommended O
doses O
for O
weight O
control O
. O

Additional O
therapy O
with O
chloroquine O
( O
CQ B
) O
was O
started O
because O
of O
arthralgia O
. O

Absolute O
and O
attributable O
risk O
of O
venous O
thromboembolism O
in O
women O
on O
combined O
cyproterone O
acetate O
and O
ethinylestradiol B
. O

OBJECTIVE O
: O
To O
achieve O
absolute O
risk O
estimates O
of O
venous O
thromboembolism O
( O
VTE O
) O
among O
women O
on O
cyproterone O
acetate O
plus O
ethinylestradiol B
( O
CPA O
/ O
EE O
) O
, O
and O
among O
women O
on O
combined O
oral O
contraceptives O
( O
COCs O
) O
. O

Flumazenil O
( O
mean O
dose O
, O
0 O
. O
76 O
mg O
) O
or O
placebo O
( O
mean O
dose O
, O
8 O
. O
9 O
ml O
) O
was O
administered O
intravenously O
to O
130 O
and O
67 O
patients O
, O
respectively O
, O
who O
had O
been O
given O
diazepam O
in O
conjunction O
with O
an O
opioid O
( O
fentanyl O
, O
meperidine B
, O
or O
morphine O
) O
for O
the O
induction O
and O
maintenance O
of O
intravenous O
conscious O
sedation O
for O
diagnostic O
or O
therapeutic O
surgical O
procedures O
. O

Conscious O
SHR O
( O
male O
300 O
- O
350 O
g O
) O
were O
subjected O
to O
90 O
degrees O
head O
- O
up O
tilts O
for O
60 O
s O
following O
acute O
administration O
of O
prazosin O
( O
0 O
. O
1 O
mg O
kg O
- O
1 O
i O
. O
p O
. O
) O
or O
rauwolscine B
( O
3 O
mg O
kg O
- O
1 O
i O
. O
v O
. O
) O
. O

The O
basal O
MAP O
of O
conscious O
SHR O
was O
reduced O
to O
a O
similar O
extent O
by O
prazosin O
( O
- O
23 O
% O
( O
- O
) O
- O
26 O
% O
MAP O
) O
and O
rauwolscine B
( O
- O
16 O
% O
( O
- O
) O
- O
33 O
% O
MAP O
) O
. O

However O
, O
the O
head O
- O
up O
tilt O
induced O
orthostatic O
hypotension O
in O
the O
SHR O
treated O
with O
prazosin O
( O
- O
16 O
% O
MAP O
, O
n O
= O
6 O
) O
, O
but O
not O
in O
the O
SHR O
treated O
with O
rauwolscine B
( O
less O
than O
+ O
2 O
% O
MAP O
, O
n O
= O
6 O
) O
. O

Conversely O
, O
administration O
of O
rauwolscine B
( O
3 O
mg O
kg O
- O
1 O
i O
. O
v O
. O
) O
in O
chronic O
prazosin O
treated O
SHR O
decreased O
the O
basal O
MAP O
by O
12 O
- O
31 O
% O
( O
n O
= O
4 O
) O
, O
and O
subsequent O
tilts O
induced O
further O
drops O
of O
MAP O
by O
19 O
- O
23 O
% O
in O
these O
rats O
. O

AIM O
: O
Hemorrhagic O
cystitis O
( O
HC O
) O
is O
a O
limiting O
side O
- O
effect O
of O
chemotherapy O
with O
ifosfamide O
( O
IFS B
) O
. O

In O
the O
study O
presented O
here O
, O
we O
investigated O
the O
use O
of O
dexamethasone O
in O
combination O
with O
mesna O
for O
the O
prevention O
of O
IFS B
- O
induced O
HC O
. O

METHODS O
: O
Male O
Wistar O
rats O
( O
150 O
- O
200 O
g O
; O
6 O
rats O
per O
group O
) O
were O
treated O
with O
saline O
or O
mesna O
5 O
min O
( O
i O
. O
p O
. O
) O
before O
and O
2 O
and O
6 O
h O
after O
( O
v O
. O
o O
. O
) O
administration O
of O
IFS B
. O

RESULTS O
: O
The O
replacement O
of O
the O
last O
dose O
or O
the O
last O
two O
doses O
of O
mesna O
with O
dexamethasone O
reduced O
the O
increase O
in O
bladder O
wet O
weight O
induced O
by O
IFS B
by O
84 O
. O
79 O
% O
and O
89 O
. O
13 O
% O
, O
respectively O
. O

In O
addition O
, O
it O
almost O
abolished O
the O
macroscopic O
and O
microscopic O
alterations O
induced O
by O
IFS B
. O

CONCLUSION O
: O
Dexamethasone O
in O
combination O
with O
mesna O
was O
efficient O
in O
blocking O
IFS B
- O
induced O
HC O
. O

Among O
several O
chemoconvulsants O
, O
bicuculline O
, O
N B
- I
methyl I
- I
D I
- I
aspartic I
acid I
and O
BAY O
k O
- O
8644 O
( O
the O
opener O
of O
L O
- O
type O
calcium O
channels O
) O
reversed O
the O
protective O
activity O
of O
loreclezole O
alone O
and O
its O
combination O
with O
valproate O
. O

Verbal O
memory O
may O
be O
especially O
sensitive O
to O
changes O
in O
oestrogen B
levels O
, O
a O
finding O
commonly O
reported O
in O
studies O
of O
hormone O
replacement O
therapy O
in O
healthy O
women O
. O

Hypersensitivity O
immune O
reaction O
as O
a O
mechanism O
for O
dilevalol B
- O
associated O
hepatitis O
. O

OBJECTIVE O
: O
To O
assess O
lymphocyte O
reactivity O
to O
dilevalol B
and O
to O
serum O
containing O
putative O
ex O
vivo O
dilevalol B
antigens O
or O
metabolites O
in O
a O
case O
of O
dilevalol B
- O
induced O
liver O
injury O
. O

PATIENT O
: O
A O
58 O
- O
year O
- O
old O
woman O
with O
a O
clinical O
diagnosis O
of O
dilevalol B
- O
induced O
liver O
injury O
. O

METHODS O
: O
Peripheral O
blood O
mononuclear O
cells O
collected O
from O
the O
patient O
were O
cultured O
in O
the O
presence O
of O
a O
solution O
of O
dilevalol B
and O
also O
with O
sera O
collected O
from O
a O
volunteer O
before O
and O
after O
dilevalol B
intake O
. O

RESULTS O
: O
No O
lymphocyte O
proliferation O
was O
observed O
either O
in O
the O
patient O
or O
in O
the O
healthy O
volunteer O
in O
the O
presence O
of O
dilevalol B
solutions O
. O

A O
significant O
proliferative O
response O
to O
serum O
collected O
after O
dilevalol B
intake O
was O
observed O
in O
the O
case O
of O
the O
patient O
compared O
with O
the O
proliferative O
response O
to O
the O
serum O
collected O
before O
the O
drug O
intake O
. O

CONCLUSIONS O
: O
The O
methodology O
used O
allowed O
the O
detection O
of O
lymphocyte O
sensitization O
to O
sera O
containing O
ex O
vivo O
- O
prepared O
dilevalol B
antigens O
, O
suggesting O
the O
involvement O
of O
an O
immunologic O
mechanism O
in O
dilevalol B
- O
induced O
liver O
injury O
. O

The O
aim O
of O
the O
study O
was O
to O
examine O
the O
influence O
of O
hyperprolactinemia O
, O
induced O
by O
haloperidol O
( O
HAL B
) O
on O
age O
related O
morphology O
and O
function O
changes O
of O
epithelial O
cells O
in O
rat O
prostate O
lateral O
lobe O
. O

Serum O
concentrations O
of O
prolactin O
( O
PRL O
) O
and O
testosterone O
( O
T B
) O
were O
measured O
. O

In O
rats O
of O
the O
experimental O
group O
, O
the O
mean O
concentration O
of O
: O
PRL O
was O
more O
than O
twice O
higher O
, O
whereas O
T B
concentration O
was O
almost O
twice O
lower O
than O
that O
in O
the O
control O
group O
. O

Two O
prodrugs O
of O
potent O
and O
selective O
GluR5 O
kainate B
receptor O
antagonists O
actives O
in O
three O
animal O
models O
of O
pain O
. O

Amino O
acids O
5 O
and O
7 O
, O
two O
potent O
and O
selective O
competitive O
GluR5 O
KA B
receptor O
antagonists O
, O
exhibited O
high O
GluR5 O
receptor O
affinity O
over O
other O
glutamate O
receptors O
. O

Five O
patients O
with O
idiopathic O
generalized O
epilepsies O
( O
IGE O
) O
treated O
with O
lamotrigine O
( O
LTG B
) O
experienced O
exacerbation O
or O
de O
novo O
appearance O
of O
myoclonic O
jerks O
( O
MJ O
) O
. O

In O
three O
patients O
, O
LTG B
exacerbated O
MJ O
in O
a O
dose O
- O
dependent O
manner O
with O
early O
aggravation O
during O
titration O
. O

MJ O
disappeared O
when O
LTG B
dose O
was O
decreased O
by O
25 O
to O
50 O
% O
. O

In O
two O
patients O
, O
LTG B
exacerbated O
MJ O
in O
a O
delayed O
but O
more O
severe O
manner O
, O
with O
myoclonic O
status O
that O
only O
ceased O
after O
LTG B
withdrawal O
. O

The O
direct O
nephrotoxic O
effects O
of O
a O
single O
dose O
of O
15 O
mg O
of O
suprofen O
were O
compared O
in O
the O
recirculating O
isolated O
rat O
kidney O
perfused O
with O
cell O
- O
free O
buffer O
with O
or O
without O
the O
addition O
of O
5 O
mg O
/ O
dL O
of O
uric B
acid I
. O

In O
contrast O
, O
a O
significant O
decline O
in O
glomerular O
filtration O
rate O
was O
found O
after O
the O
introduction O
of O
suprofen O
to O
the O
kidney O
perfused O
with O
uric B
acid I
; O
no O
changes O
were O
found O
with O
suprofen O
in O
the O
absence O
of O
uric B
acid I
. O

A O
significant O
decrease O
in O
the O
baseline O
excretion O
rate O
of O
uric B
acid I
was O
found O
in O
rats O
given O
suprofen O
, O
compared O
with O
drug O
- O
free O
controls O
. O

However O
, O
the O
fractional O
excretion O
of O
uric B
acid I
was O
unchanged O
between O
the O
groups O
over O
the O
experimental O
period O
. O

In O
summary O
, O
suprofen O
causes O
acute O
declines O
in O
renal O
function O
, O
most O
likely O
by O
directly O
altering O
the O
intrarenal O
distribution O
of O
uric B
acid I
. O

PTU B
- O
associated O
vasculitis O
in O
a O
girl O
with O
Turner O
Syndrome O
and O
Graves O
' O
disease O
. O

The O
diagnosis O
of O
propylthiouracil O
( O
PTU B
) O
- O
associated O
vasculitis O
was O
made O
by O
observation O
of O
consistent O
clinical O
features O
, O
the O
detection O
of O
elevated O
ANA O
and O
ANCA O
in O
the O
blood O
, O
and O
the O
observed O
clinical O
resolution O
of O
symptoms O
following O
withdrawal O
of O
PTU B
. O

( O
Anacardiaceae O
) O
, O
on O
isoproterenol O
( O
ISPH B
) O
- O
induced O
myocardial O
infarction O
( O
MI O
) O
in O
rats O
through O
its O
antioxidative O
mechanism O
. O

Subcutaneous O
injection O
of O
ISPH B
( O
200 O
mg O
/ O
kg O
body O
weight O
in O
1 O
ml O
saline O
) O
to O
rats O
for O
2 O
consecutive O
days O
caused O
myocardial O
damage O
in O
rat O
heart O
, O
which O
was O
determined O
by O
the O
increased O
activity O
of O
serum O
lactate O
dehydrogenase O
( O
LDH O
) O
and O
creatine O
phosphokinase O
isoenzymes O
( O
CK O
- O
MB O
) O
, O
increased O
uric B
acid I
level O
and O
reduced O
plasma O
iron O
binding O
capacity O
. O

Activities O
of O
heart O
tissue O
enzymic O
antioxidants O
and O
serum O
non O
- O
enzymic O
antioxidants O
levels O
rose O
significantly O
upon O
mangiferin O
administration O
as O
compared O
to O
ISPH B
- O
induced O
MI O
rats O
. O

From O
the O
present O
study O
it O
is O
concluded O
that O
mangiferin O
exerts O
a O
beneficial O
effect O
against O
ISPH B
- O
induced O
MI O
due O
to O
its O
antioxidant O
potential O
, O
which O
regulated O
the O
tissues O
defense O
system O
against O
cardiac O
damage O
. O

A O
comparison O
of O
individual O
selective O
and O
unselective O
cyclooxygenase O
inhibitors O
suggests O
substance O
- O
specific O
differences O
, O
which O
may O
depend O
on O
differences O
in O
pharmacokinetic O
parameters O
or O
inhibitory O
potency O
and O
may O
be O
contributed O
by O
prostaglandin B
- O
independent O
effects O
. O

PURPOSE O
: O
NGF O
and O
PGs B
in O
the O
bladder O
can O
be O
affected O
by O
pathological O
changes O
in O
the O
bladder O
and O
these O
changes O
can O
be O
detected O
in O
urine O
. O

We O
investigated O
changes O
in O
urinary O
NGF O
and O
PGs B
in O
women O
with O
OAB O
. O

NGF O
, O
PGE2 O
, O
PGF2alpha B
and O
PGI2 B
were O
measured O
using O
enzyme O
- O
linked O
immunosorbent O
assay O
and O
compared O
between O
the O
groups O
. O

RESULTS O
: O
Urinary O
NGF O
, O
PGE2 O
and O
PGF2alpha B
were O
significantly O
increased O
in O
patients O
with O
OAB O
compared O
with O
controls O
( O
p O
< O
0 O
. O
05 O
) O
. O

However O
, O
urinary O
PGI2 B
was O
not O
different O
between O
controls O
and O
patients O
with O
OAB O
. O

Urinary O
NGF O
, O
PGF2alpha B
and O
PGI2 B
did O
not O
correlate O
with O
urodynamic O
parameters O
in O
patients O
with O
OAB O
. O

CONCLUSIONS O
: O
NGF O
and O
PGs B
have O
important O
roles O
in O
the O
development O
of O
OAB O
symptoms O
in O
female O
patients O
. O

To O
assess O
the O
antioxidant O
effects O
of O
atorvastatin O
( O
atorva B
) O
on O
dexamethasone O
( O
dex O
) O
- O
induced O
hypertension O
, O
60 O
male O
Sprague O
- O
Dawley O
rats O
were O
treated O
with O
atorva B
30 O
mg O
/ O
kg O
/ O
day O
or O
tap O
water O
for O
15 O
days O
. O

In O
this O
prevention O
study O
, O
SBP O
in O
the O
atorva B
+ O
dex O
group O
was O
increased O
from O
115 O
+ O
/ O
- O
0 O
. O
4 O
to O
124 O
+ O
/ O
- O
1 O
. O
5 O
mmHg O
, O
but O
this O
was O
significantly O
lower O
than O
in O
the O
dex O
- O
only O
group O
( O
P O
' O
< O
0 O
. O
05 O
) O
. O

Atorva B
reversed O
dex O
- O
induced O
hypertension O
( O
129 O
+ O
/ O
- O
0 O
. O
6 O
mmHg O
, O
vs O
. O
135 O
+ O
/ O
- O
0 O
. O
6 O
mmHg O
P O
' O
< O
0 O
. O
05 O
) O
and O
decreased O
plasma O
superoxide O
( O
7931 O
+ O
/ O
- O
392 O
. O
8 O
dex O
, O
1187 O
+ O
/ O
- O
441 O
. O
2 O
atorva B
+ O
dex O
, O
P O
< O
0 O
. O
0001 O
) O
. O

Atorva B
affected O
neither O
plasma O
NOx O
nor O
thymus O
weight O
. O

Methamphetamine O
( O
MA B
) O
- O
induced O
dopaminergic O
neurotoxicity O
is O
believed O
to O
be O
associated O
with O
the O
increased O
formation O
of O
free O
radicals O
. O

This O
study O
examined O
the O
effect O
of O
alpha O
- O
tocopherol O
( O
alpha B
- I
TC I
) O
, O
a O
scavenger O
of O
reactive O
oxygen O
species O
, O
and O
deferoxamine O
( O
DFO O
) O
, O
an O
iron O
chelator O
, O
on O
the O
MA B
- O
induced O
neurotoxicity O
. O

Male O
rats O
were O
treated O
with O
MA B
( O
10 O
mg O
/ O
kg O
, O
every O
2 O
h O
for O
four O
injections O
) O
. O

The O
rat O
received O
either O
alpha B
- I
TC I
( O
20 O
mg O
/ O
kg O
) O
intraperitoneally O
for O
3 O
days O
and O
30 O
min O
prior O
to O
MA B
administration O
or O
DFO O
( O
50 O
mg O
/ O
kg O
) O
subcutaneously O
30 O
min O
before O
MA B
administration O
. O

The O
concentrations O
of O
dopamine O
( O
DA O
) O
, O
serotonin O
and O
their O
metabolites O
decreased O
significantly O
after O
MA B
administration O
, O
which O
was O
inhibited O
by O
the O
alpha B
- I
TC I
and O
DFO O
pretreatment O
. O

alpha B
- I
TC I
and O
DFO O
attenuated O
the O
MA B
- O
induced O
hyperthermia O
as O
well O
as O
the O
alterations O
in O
the O
locomotor O
activity O
. O

The O
level O
of O
lipid O
peroxidation O
was O
higher O
and O
the O
reduced O
glutathione O
concentration O
was O
lower O
in O
the O
MA B
- O
treated O
rats O
. O

These O
changes O
were O
significantly O
attenuated O
by O
alpha B
- I
TC I
and O
DFO O
. O

This O
suggests O
that O
alpha B
- I
TC I
and O
DFO O
ameliorate O
the O
MA B
- O
induced O
neuronal O
damage O
by O
decreasing O
the O
level O
of O
oxidative O
stress O
. O

Two O
studies O
evaluated O
quetiapine O
( O
up O
to O
800 O
mg O
/ O
day O
) O
in O
combination O
with O
a O
mood O
stabilizer O
( O
lithium O
or O
divalproex B
, O
QTP O
+ O
Li O
/ O
DVP B
) O
( O
n O
= O
196 O
) O
compared O
to O
placebo O
and O
mood O
stabilizer O
( O
PBO O
+ O
Li O
/ O
DVP B
) O
( O
n O
= O
203 O
) O
. O

Similarly O
, O
EPS O
- O
related O
adverse O
events O
with O
QTP O
+ O
Li O
/ O
DVP B
( O
21 O
. O
4 O
% O
) O
were O
no O
different O
than O
with O
PBO O
+ O
Li O
/ O
DVP B
( O
19 O
. O
2 O
% O
) O
. O

The O
incidence O
of O
akathisia O
was O
low O
and O
similar O
with O
quetiapine O
monotherapy O
( O
3 O
. O
3 O
% O
) O
and O
placebo O
( O
6 O
. O
1 O
% O
) O
, O
and O
with O
QTP O
+ O
Li O
/ O
DVP B
( O
3 O
. O
6 O
% O
) O
and O
PBO O
+ O
Li O
/ O
DVP B
( O
4 O
. O
9 O
% O
) O
. O

At O
puberty O
( O
P40 O
) O
, O
half O
the O
PCPA O
- O
treated O
rats O
and O
half O
the O
saline O
- O
treated O
rats O
began O
treatment O
with O
testosterone O
( O
T B
, O
5 O
mg O
/ O
kg O
, O
5 O
days O
/ O
week O
) O
. O

Chronic O
T B
treatment O
significantly O
decreased O
5 O
- O
HT O
and O
5 O
- O
HIAA O
in O
certain O
brain O
areas O
, O
but O
to O
a O
much O
lesser O
extent O
than O
PCPA O
. O

T B
alone O
had O
no O
effect O
on O
locomotion O
, O
irritability O
, O
or O
sexual O
behavior O
but O
increased O
partner O
preference O
and O
aggression O
. O

The O
most O
striking O
effect O
of O
combining O
T B
+ O
PCPA O
was O
a O
significant O
increase O
in O
attack O
frequency O
as O
well O
as O
a O
significant O
decrease O
in O
the O
latency O
to O
attack O
, O
particularly O
following O
physical O
provocation O
. O

Syncope O
and O
QT O
prolongation O
among O
patients O
treated O
with O
methadone O
for O
heroin B
dependence O
in O
the O
city O
of O
Copenhagen O
. O

BACKGROUND O
: O
Methadone O
is O
prescribed O
to O
heroin B
addicts O
to O
decrease O
illicit O
opioid O
use O
. O

As O
heroin B
addicts O
sometimes O
faint O
while O
using O
illicit O
drugs O
, O
doctors O
might O
attribute O
too O
many O
episodes O
of O
syncope O
to O
illicit O
drug O
use O
and O
thereby O
underestimate O
the O
incidence O
of O
TdP O
in O
this O
special O
population O
, O
and O
the O
high O
mortality O
in O
this O
population O
may O
, O
in O
part O
, O
be O
caused O
by O
the O
proarrhythmic O
effect O
of O
methadone O
. O

METHODS O
: O
In O
this O
cross O
- O
sectional O
study O
interview O
, O
ECGs O
and O
blood O
samples O
were O
collected O
in O
a O
population O
of O
adult O
heroin B
addicts O
treated O
with O
methadone O
or O
buprenorphine O
on O
a O
daily O
basis O
. O

CONCLUSIONS O
: O
Methadone O
is O
associated O
with O
QT O
prolongation O
and O
higher O
reporting O
of O
syncope O
in O
a O
population O
of O
heroin B
addicts O
. O

An O
extremely O
rare O
case O
of O
delusional O
parasitosis O
in O
a O
chronic O
hepatitis O
C O
patient O
during O
pegylated B
interferon I
alpha I
- I
2b I
and O
ribavirin O
treatment O
. O

We O
present O
a O
49 O
- O
year O
- O
old O
woman O
who O
developed O
a O
delusional O
parasitosis O
during O
treatment O
with O
pegylated B
interferon I
alpha I
- I
2b I
weekly O
and O
ribavirin O
. O

All O
the O
complaints O
disappeared O
after O
stopping O
pegylated B
interferon I
alpha I
- I
2b I
and O
reappeared O
after O
restarting O
it O
. O

Phenobarbital O
( O
PB B
) O
has O
a O
reputation O
for O
safety O
, O
and O
it O
is O
commonly O
believed O
that O
PB B
- O
related O
increases O
in O
serum O
aminotransferase O
levels O
do O
not O
indicate O
or O
predict O
the O
development O
of O
significant O
chronic O
liver O
disease O
. O

Here O
we O
report O
of O
two O
adult O
patients O
with O
a O
long O
history O
of O
epilepsy O
treated O
with O
PB B
who O
died O
suddenly O
: O
one O
as O
consequence O
of O
cardiac O
arrest O
, O
the O
other O
of O
acute O
bronchopneumonia O
. O

Our O
findings O
illustrate O
that O
PB B
may O
be O
associated O
with O
chronic O
liver O
damage O
, O
which O
may O
lead O
to O
more O
serious O
and O
deleterious O
consequences O
. O

For O
this O
reason O
, O
each O
clinician O
should O
recognize O
this O
entity O
in O
the O
differential O
diagnosis O
of O
PB B
- O
related O
asymptomatic O
chronic O
hepatic O
enzyme O
dysfunction O
. O

METHODS O
AND O
RESULTS O
: O
In O
order O
to O
investigate O
whether O
the O
HAART O
component O
zidovudine O
( O
3 B
' I
- I
azido I
- I
2 I
' I
, I
3 I
' I
- I
deoxythymidine I
; O
AZT O
) O
triggers O
the O
Fas O
- O
dependent O
cell O
- O
death O
pathway O
and O
cause O
cytoskeletal O
disruption O
in O
a O
murine O
model O
of O
DCM O
, O
8 O
- O
week O
- O
old O
transgenic O
( O
expressing O
Fas O
ligand O
in O
the O
myocardium O
: O
FasL O
Tg O
) O
and O
non O
- O
transgenic O
( O
NTg O
) O
mice O
received O
water O
ad O
libitum O
containing O
different O
concentrations O

INTRODUCTION O
: O
The O
possible O
anxiogenic O
effects O
of O
fluoroquinolones B
, O
namely O
ciprofloxacin O
and O
norfloxacin O
, O
were O
investigated O
in O
adult O
Charles O
Foster O
albino O
rats O
of O
either O
sex O
, O
weighing O
150 O
- O
200 O
g O
. O

Exaggerated O
expression O
of O
inflammatory O
mediators O
in O
vasoactive O
intestinal O
polypeptide O
knockout O
( O
VIP O
- O
/ O
- O
) O
mice O
with O
cyclophosphamide O
( O
CYP B
) O
- O
induced O
cystitis O
. O

VIP O
( O
- O
/ O
- O
) O
mice O
exhibit O
altered O
bladder O
function O
and O
neurochemical O
properties O
in O
micturition O
pathways O
after O
cyclophosphamide O
( O
CYP B
) O
- O
induced O
cystitis O
. O

A O
mouse O
inflammatory O
cytokine O
and O
receptor O
RT2 O
profiler O
array O
was O
used O
to O
determine O
regulated O
transcripts O
in O
the O
urinary O
bladder O
of O
wild O
type O
( O
WT O
) O
and O
VIP O
( O
- O
/ O
- O
) O
mice O
with O
or O
without O
CYP B
- O
induced O
cystitis O
( O
150 O
mg O
/ O
kg O
; O
i O
. O
p O
. O
; O
48 O
h O
) O
. O

Four O
binary O
comparisons O
were O
made O
: O
WT O
control O
versus O
CYP B
treatment O
( O
48 O
h O
) O
, O
VIP O
( O
- O
/ O
- O
) O
control O
versus O
CYP B
treatment O
( O
48 O
h O
) O
, O
WT O
control O
versus O
VIP O
( O
- O
/ O
- O
) O
control O
, O
and O
WT O
with O
CYP B
treatment O
( O
48 O
h O
) O
versus O
VIP O
( O
- O
/ O
- O
) O
with O
CYP B
treatment O
( O
48 O
h O
) O
. O

CYP B
treatment O
significantly O
( O
p O
< O
or O
= O
0 O
. O
001 O
) O
increased O
expression O
of O
CXCL1 O
and O
IL O
- O
1beta O
in O
the O
urinary O
bladder O
of O
WT O
and O
VIP O
( O
- O
/ O
- O
) O
mice O
, O
but O
expression O
in O
VIP O
( O
- O
/ O
- O
) O
mice O
with O
CYP B
treatment O
was O
significantly O
( O
p O
< O
or O
= O
0 O
. O
001 O
) O
greater O
( O
4 O
. O
2 O
- O
to O
13 O
- O
fold O
increase O
) O
than O
that O
observed O
in O
WT O
urinary O
bladder O
( O
3 O
. O
6 O
- O
to O
5 O
- O
fold O
increase O
) O
. O

The O
data O
suggest O
that O
in O
VIP O
( O
- O
/ O
- O
) O
mice O
with O
bladder O
inflammation O
, O
inflammatory O
mediators O
are O
increased O
above O
that O
observed O
in O
WT O
with O
CYP B
. O

BACKGROUND O
: O
Unfractionated B
heparin I
sodium I
( O
UFH B
) O
or O
low O
- O
molecular O
weight O
heparin O
( O
LMWH O
) O
is O
used O
in O
anticoagulant O
protocols O
at O
several O
institutions O
to O
prevent O
thrombosis O
after O
liver O
transplantation O
. O

We O
started O
LMWH O
( O
25 O
IU O
/ O
kg O
/ O
h O
) O
on O
postoperative O
day O
( O
POD O
) O
1 O
, O
switching O
to O
UFH B
( O
5000 O
U O
/ O
d O
) O
on O
POD O
2 O
or O
3 O
. O

The O
dose O
of O
UFH B
was O
changed O
according O
to O
the O
activated O
clotting O
time O
level O
. O

None O
of O
the O
subjects O
/ O
patients O
developed O
UFH B
- O
related O
HIT O
. O

After O
a O
short O
period O
of O
basal O
activity O
recording O
, O
epileptic O
focus O
was O
induced O
by O
injecting O
400IU O
/ O
2 O
microl O
penicillin B
- I
G I
potassium I
into O
the O
left O
lateral O
ventricle O
while O
the O
cortical O
activity O
was O
continuously O
recorded O
. O

Doxorubicin O
toxicokinetics O
studies O
revealed O
no O
change O
in O
accumulation O
of O
doxorubicin O
and O
doxorubicinol B
( O
toxic O
metabolite O
) O
in O
the O
normal O
diet O
- O
fed O
( O
ND O
) O
and O
OB O
hearts O
. O

METHODS O
: O
We O
investigated O
the O
effect O
of O
varying O
the O
intraperitoneal O
infusion O
rates O
of O
bupropion B
HCl I
120 O
mg O
/ O
kg O
, O
a O
known O
convulsive O
dose O
50 O
( O
CD50 O
) O
, O
on O
the O
incidence O
and O
severity O
of O
bupropion O
- O
induced O
convulsions O
in O
the O
Swiss O
albino O
mice O
. O

A O
total O
of O
69 O
mice O
, O
approximately O
7 O
weeks O
of O
age O
, O
and O
weighing O
21 O
. O
0 O
to O
29 O
. O
1 O
g O
were O
randomly O
assigned O
to O
bupropion B
HCl I
120 O
mg O
/ O
kg O
treatment O
by O
intraperitoneal O
( O
IP O
) O
administration O
in O
7 O
groups O
( O
9 O
to O
10 O
animals O
per O
group O
) O
. O

Bupropion B
HCl I
was O
infused O
through O
a O
surgically O
implanted O
IP O
dosing O
catheter O
with O
infusions O
in O
each O
group O
of O
0 O
min O
, O
15 O
min O
, O
30 O
min O
, O
60 O
min O
, O
90 O
min O
, O
120 O
min O
, O
and O
240 O
min O
. O

RESULTS O
: O
The O
results O
showed O
that O
IP O
administration O
of O
bupropion B
HCl I
120 O
mg O
/ O
kg O
by O
bolus O
injection O
induced O
convulsions O
in O
6 O
out O
of O
10 O
mice O
( O
60 O
% O
of O
convulsing O
mice O
) O
in O
group O
1 O
. O

Logistic O
regression O
analysis O
revealed O
that O
infusion O
time O
was O
significant O
( O
p O
= O
0 O
. O
0004 O
; O
odds O
ratio O
= O
0 O
. O
974 O
) O
and O
increasing O
the O
IP O
infusion O
time O
of O
bupropion B
HCl I
120 O
mg O
/ O
kg O
was O
associated O
with O
a O
91 O
% O
reduced O
odds O
of O
convulsions O
at O
infusion O
times O
of O
15 O
to O
90 O
min O
compared O
to O
bolus O
injection O
. O

The O
hemodynamic O
effects O
of O
captopril O
and O
other O
angiotensin B
- I
converting I
enzyme I
inhibitors I
may O
be O
mediated O
by O
the O
endogenous O
opioid O
system O
. O

5 B
flourouracil I
- O
induced O
apical O
ballooning O
syndrome O
: O
a O
case O
report O
. O

She O
underwent O
recent O
chemotherapy O
with O
fluorouracil B
for O
metastatic O
colorectal O
cancer O
. O

HT O
included O
oestrogens B
, O
with O
or O
without O
progestogens B
, O
via O
oral O
, O
transdermal O
, O
subcutaneous O
or O
transnasal O
routes O
. O

Long O
- O
term O
oestrogen B
- O
only O
HT O
significantly O
increased O
the O
risk O
of O
venous O
thrombo O
- O
embolism O
, O
stroke O
and O
gallbladder O
disease O
( O
after O
one O
to O
two O
years O
, O
three O
years O
and O
seven O
years O
' O
use O
respectively O
) O
, O
but O
did O
not O
significantly O
increase O
the O
risk O
of O
breast O
cancer O
. O

Among O
women O
with O
cardiovascular O
disease O
, O
long O
- O
term O
use O
of O
combined O
continuous O
HT O
significantly O
increased O
the O
risk O
of O
venous O
thrombo O
- O
embolism O
. O
One O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year O
old O
women O
taking O
combined O
continuous O
HT O
and O
1637 O
taking O
oestrogen B
- O
only O
HT O
, O
versus O
similar O
- O
sized O
placebo O
groups O
. O

However O
, O
the O
involvement O
of O
a O
specific O
, O
terminal O
prostaglandin B
( O
PG O
) O
isomerase O
has O
not O
been O
evaluated O
. O

Moreover O
, O
M O
( O
3 O
) O
- O
muscarinic O
acetylcholine O
receptor O
( O
mAChR O
) O
antagonist O
4 O
- O
DAMP O
( O
4 B
- I
diphenylacetoxy I
- I
N I
- I
methylpiperidine I
- I
methiodide I
) O
partially O
abolished O
the O
beneficial O
effects O
of O
pilocarpine O
. O

Effect O
of O
Hibiscus B
rosa I
sinensis I
on O
reserpine O
- O
induced O
neurobehavioral O
and O
biochemical O
alterations O
in O
rats O
. O

Effect O
of O
methanolic O
extract O
of O
Hibiscus B
rosa I
sinensis I
( O
100 O
- O
300 O
mg O
/ O
kg O
) O
was O
studied O
on O
reserpine O
- O
induced O
orofacial O
dyskinesia O
and O
neurochemical O
alterations O
. O

Reserpine O
treated O
rats O
significantly O
developed O
vacuous O
chewing O
movements O
and O
tongue O
protrusions O
however O
, O
coadministration O
of O
Hibiscus B
rosa I
sinensis I
roots O
extract O
( O
100 O
, O
200 O
and O
300 O
mg O
/ O
kg O
, O
per O
orally O
) O
attenuated O
the O
effects O
. O

The O
results O
of O
the O
present O
study O
suggested O
that O
Hibiscus B
rosa I
sinensis I
had O
a O
protective O
role O
against O
reserpine O
- O
induced O
orofacial O
dyskinesia O
and O
oxidative O
stress O
. O

We O
tested O
the O
hypothesis O
that O
nimodipine O
( O
NIMO B
) O
administered O
at O
the O
onset O
of O
nitroglycerin O
( O
NTG B
) O
- O
induced O
hypotension O
would O
preserve O
long O
- O
term O
associative O
memory O
. O

Ninety O
- O
six O
Swiss O
- O
Webster O
mice O
( O
30 O
- O
35 O
g O
, O
6 O
- O
8 O
wk O
) O
, O
were O
randomized O
into O
6 O
groups O
1 O
) O
saline O
( O
control O
) O
, O
2 O
) O
NTG B
immediately O
after O
learning O
, O
3 O
) O
NTG B
3 O
h O
after O
learning O
, O
4 O
) O
NTG B
and O
NIMO B
, O
5 O
) O
vehicle O
, O
and O
6 O
) O
NIMO B
alone O
. O

Mice O
subjected O
to O
hypotensive O
episodes O
showed O
a O
significant O
decrease O
in O
latency O
time O
( O
178 O
+ O
/ O
- O
156 O
s O
) O
compared O
with O
those O
injected O
with O
saline O
, O
NTG B
+ O
NIMO B
, O
or O
delayed O
NTG B
( O
580 O
+ O
/ O
- O
81 O
s O
, O
557 O
+ O
/ O
- O
67 O
s O
, O
and O
493 O
+ O
/ O
- O
146 O
s O
, O
respectively O
) O
. O

In O
a O
separate O
group O
of O
mice O
not O
subjected O
to O
behavioral O
studies O
, O
the O
same O
dose O
of O
NTG B
( O
n O
= O
3 O
) O
and O
NTG B
+ O
NIMO B
( O
n O
= O
3 O
) O
caused O
mean O
arterial O
blood O
pressure O
to O
decrease O
from O
85 O
. O
9 O
+ O
/ O
- O
3 O
. O
8 O
mm O
Hg O
sem O
to O
31 O
. O
6 O
+ O
/ O
- O
0 O
. O
8 O
mm O
Hg O
sem O
and O
from O
86 O
. O
2 O
+ O
/ O
- O
3 O
. O
7 O
mm O
Hg O
sem O
to O
32 O
. O
6 O
+ O
/ O
- O
0 O
. O
2 O
mm O
Hg O
sem O
, O
respectively O
. O

Mean O
arterial O
blood O
pressure O
in O
mice O
treated O
with O
NIMO B
alone O
decreased O
from O
88 O
. O
1 O
+ O
/ O
- O
3 O
. O
8 O
mm O
Hg O
to O
80 O
. O
0 O
+ O
/ O
- O
2 O
. O
9 O
mm O
Hg O
. O

PbtO O
( O
2 O
) O
decreased O
from O
51 O
. O
7 O
+ O
/ O
- O
4 O
. O
5 O
mm O
Hg O
sem O
to O
33 O
. O
8 O
+ O
/ O
- O
5 O
. O
2 O
mm O
Hg O
sem O
in O
the O
NTG B
group O
and O
from O
38 O
. O
6 O
+ O
/ O
- O
6 O
. O
1 O
mm O
Hg O
sem O
to O
25 O
. O
4 O
+ O
/ O
- O
2 O
. O
0 O
mm O
Hg O
sem O
in O
the O
NTG B
+ O
NIMO B
groups O
, O
respectively O
. O

CONCLUSION O
: O
In O
a O
PA O
retention O
paradigm O
, O
the O
injection O
of O
NTG B
immediately O
after O
learning O
produced O
a O
significant O
impairment O
of O
long O
- O
term O
associative O
memory O
in O
mice O
, O
whereas O
delayed O
induced O
hypotension O
had O
no O
effect O
. O

NIMO B
attenuated O
the O
disruption O
in O
consolidation O
of O
long O
- O
term O
memory O
caused O
by O
NTG B
but O
did O
not O
improve O
latency O
in O
the O
absence O
of O
hypotension O
. O

The O
observed O
effect O
of O
NIMO B
may O
have O
been O
attributable O
to O
the O
preservation O
of O
calcium O
homeostasis O
during O
hypotension O
, O
because O
there O
were O
no O
differences O
in O
the O
PbtO O
( O
2 O
) O
indices O
among O
groups O
. O

These O
events O
were O
temporally O
coincident O
with O
the O
initial O
use O
of O
high O
- O
dose O
tranexamic O
acid O
( O
TXA B
) O
therapy O
after O
withdrawal O
of O
aprotinin O
from O
general O
clinical O
usage O
. O

The O
purpose O
of O
this O
review O
was O
to O
perform O
a O
retrospective O
analysis O
to O
examine O
whether O
there O
was O
a O
relation O
between O
TXA B
usage O
and O
seizures O
after O
cardiac O
surgery O
. O

All O
24 O
patients O
with O
seizures O
received O
high O
doses O
of O
TXA B
intraoperatively O
ranging O
from O
61 O
to O
259 O
mg O
/ O
kg O
, O
had O
a O
mean O
age O
of O
69 O
. O
9 O
years O
, O
and O
21 O
of O
24 O
had O
undergone O
open O
chamber O
rather O
than O
coronary O
bypass O
procedures O
. O

CONCLUSION O
: O
Our O
results O
suggest O
that O
use O
of O
high O
- O
dose O
TXA B
in O
older O
patients O
in O
conjunction O
with O
cardiopulmonary O
bypass O
and O
open O
- O
chamber O
cardiac O
surgery O
is O
associated O
with O
clinical O
seizures O
in O
susceptible O
patients O
. O

Supraventricular O
tachycardia O
developed O
in O
one O
patient O
receiving O
Thorazine B
( O
chlorpromazine O
) O
. O

Aventyl O
( O
nortriptyline O
) O
and O
Elavil B
( O
amitriptyline O
) O
each O
produced O
left O
bundle O
branch O
block O
in O
a O
73 O
year O
old O
woman O
. O

The O
anaemia O
induced O
by O
3 B
' I
- I
azido I
- I
3 I
' I
dideoxythymidine I
( O
AZT O
) O
is O
poorly O
understood O
. O

Risk O
of O
nephropathy O
after O
consumption O
of O
nonionic O
contrast B
media I
by O
children O
undergoing O
cardiac O
angiography O
: O
a O
prospective O
study O
. O

Despite O
increasing O
reports O
on O
nonionic O
contrast B
media I
- O
induced O
nephropathy O
( O
CIN O
) O
in O
hospitalized O
adult O
patients O
during O
cardiac O
procedures O
, O
the O
studies O
in O
pediatrics O
are O
limited O
, O
with O
even O
less O
focus O
on O
possible O
predisposing O
factors O
and O
preventive O
measures O
for O
patients O
undergoing O
cardiac O
angiography O
. O

This O
prospective O
study O
determined O
the O
incidence O
of O
CIN O
for O
two O
nonionic O
contrast B
media I
( O
CM B
) O
, O
iopromide O
and O
iohexol O
, O
among O
80 O
patients O
younger O
than O
18 O
years O
and O
compared O
the O
rates O
for O
this O
complication O
in O
relation O
to O
the O
type O
and O
dosage O
of O
CM B
and O
the O
presence O
of O
cyanosis O
. O

Serum O
sodium O
( O
Na O
) O
, O
potassium O
( O
K O
) O
, O
and O
creatinine O
( O
Cr O
) O
were O
measured O
24 O
h O
before O
angiography O
as O
baseline O
values O
, O
then O
measured O
again O
at O
12 O
- O
, O
24 O
- O
, O
and O
48 O
- O
h O
intervals O
after O
CM B
use O
. O

Whereas O
33 O
. O
3 O
% O
of O
the O
patients O
with O
CIN O
were O
among O
those O
who O
received O
the O
proper O
dosage O
of O
CM B
, O
the O
percentage O
increased O
to O
66 O
. O
6 O
% O
among O
those O
who O
received O
larger O
doses O
, O
with O
a O
significant O
difference O
in O
the O
incidence O
of O
CIN O
related O
to O
the O
different O
dosages O
of O
CM B
( O
p O
= O
0 O
. O
014 O
) O
. O

The O
incidence O
depends O
on O
dosage O
but O
not O
on O
the O
type O
of O
consumed O
nonionic O
CM B
, O
nor O
on O
the O
presence O
of O
cyanosis O
, O
and O
although O
CIN O
usually O
is O
reversible O
, O
more O
concern O
is O
needed O
for O
the O
prevention O
of O
such O
a O
complication O
in O
children O
. O

METHODS O
: O
Male O
Wistar O
rats O
received O
each O
dose O
of O
the O
alpha O
( O
2 O
) O
- O
adrenoceptor O
antagonist O
yohimbine O
( O
0 O
. O
25 O
- O
1 O
. O
0mg O
/ O
kg O
) O
, O
the O
5 O
- O
HT O
( O
2C O
) O
receptor O
agonist O
m O
- O
chlorophenylpiperazine O
( O
mCPP O
, O
0 O
. O
5 O
- O
2 O
. O
0mg O
/ O
kg O
) O
or O
the O
GABA O
( O
A O
) O
inverse O
receptor O
agonist O
pentylenetetrazole B
( O
PTZ O
, O
3 O
- O
30mg O
/ O
kg O
) O
and O
were O
subsequently O
tested O
in O
either O
LES O
or O
FPS O
. O

Coenzyme O
Q10 O
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced B
glutathione I
level O
and O
superoxide O
dismutase O
activity O
) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor O
necrosis O
factor O
- O
alpha O
, O
nitric O
oxide O
and O
platinum O
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium O
and O
zinc O
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin O
administration O
. O

Here O
we O
show O
that O
the O
recently O
reported O
ability O
of O
L B
- I
dihydroxyphenylalanine I
to O
reverse O
the O
protective O
effect O
of O
alpha B
- I
methyl I
- I
para I
- I
tyrosine I
on O
METH O
- O
induced O
DA O
neurotoxicity O
is O
also O
confounded O
by O
drug O
effects O
on O
body O
temperature O
. O

The O
condition O
is O
treated O
with O
intravenous O
thyroxine O
( O
T4 B
) O
or O
intravenous O
tri O
- O
iodo O
- O
thyronine O
( O
T3 O
) O
. O

Effects O
of O
active O
constituents O
of O
Crocus O
sativus O
L O
. O
, O
crocin O
on O
streptozocin B
- O
induced O
model O
of O
sporadic O
Alzheimer O
' O
s O
disease O
in O
male O
rats O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
crocins O
on O
sporadic O
Alzheimer O
' O
s O
disease O
induced O
by O
intracerebroventricular O
( O
icv O
) O
streptozocin B
( O
STZ B
) O
in O
male O
rats O
was O
investigated O
. O

METHODS O
: O
Male O
adult O
Wistar O
rats O
( O
n O
= O
90 O
and O
260 O
- O
290 O
g O
) O
were O
divided O
into O
1 O
, O
control O
; O
2 O
and O
3 O
, O
crocins O
( O
15 O
and O
30 O
mg O
/ O
kg O
) O
; O
4 O
, O
STZ B
; O
5 O
and O
6 O
, O
STZ B
+ O
crocins O
( O
15 O
and O
30 O
mg O
/ O
kg O
) O
groups O
. O

In O
Alzheimer O
' O
s O
disease O
groups O
, O
rats O
were O
injected O
with O
STZ B
- O
icv O
bilaterally O
( O
3 O
mg O
/ O
kg O
) O
in O
first O
day O
and O
3 O
days O
later O
, O
a O
similar O
STZ B
- O
icv O
application O
was O
repeated O
. O

In O
STZ B
+ O
crocin O
animal O
groups O
, O
crocin O
was O
applied O
in O
doses O
of O
15 O
and O
30 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
one O
day O
pre O
- O
surgery O
and O
continued O
for O
three O
weeks O
. O

RESULTS O
: O
It O
was O
found O
out O
that O
crocin O
( O
30 O
mg O
/ O
kg O
) O
- O
treated O
STZ B
- O
injected O
rats O
show O
higher O
correct O
choices O
and O
lower O
errors O
in O
Y O
- O
maze O
than O
vehicle O
- O
treated O
STZ B
- O
injected O
rats O
. O

In O
addition O
, O
crocin O
in O
the O
mentioned O
dose O
could O
significantly O
attenuated O
learning O
and O
memory O
impairment O
in O
treated O
STZ B
- O
injected O
group O
in O
passive O
avoidance O
test O
. O

CONCLUSION O
: O
Therefore O
, O
these O
results O
demonstrate O
the O
effectiveness O
of O
crocin O
( O
30 O
mg O
/ O
kg O
) O
in O
antagonizing O
the O
cognitive O
deficits O
caused O
by O
STZ B
- O
icv O
in O
rats O
and O
its O
potential O
in O
the O
treatment O
of O
neurodegenerative O
diseases O
such O
as O
Alzheimer O
' O
s O
disease O
. O

In O
group O
- O
1 O
( O
n O
= O
10 O
) O
hippocampal O
DBS O
was O
off O
and O
in O
the O
group O
- O
2 O
( O
n O
= O
10 O
) O
hippocampal O
DBS O
was O
on O
( O
185 O
Hz O
, O
0 O
. O
5V O
, O
1V O
, O
2V O
, O
and O
5V O
for O
60 O
sec O
) O
following O
penicillin B
G I
injection O
intracortically O
. O

EEG O
recordings O
were O
obtained O
before O
and O
15 O
minutes O
following O
penicillin B
- I
G I
injection O
, O
and O
at O
10th O
minutes O
following O
each O
stimulus O
for O
analysis O
in O
terms O
of O
frequency O
, O
amplitude O
, O
and O
power O
spectrum O
. O

Continuous O
ambulatory O
ECG O
monitoring O
during O
fluorouracil B
therapy O
: O
a O
prospective O
study O
. O

Although O
there O
have O
been O
anecdotal O
reports O
of O
cardiac O
toxicity O
associated O
with O
fluorouracil B
( O
5 O
- O
FU O
) O
therapy O
, O
this O
phenomenon O
has O
not O
been O
studied O
in O
a O
systematic O
fashion O
. O

This O
program O
consists O
of O
double O
screenings O
of O
pregnant O
women O
and O
prophylactic O
treatment O
to O
the O
infants O
born O
to O
both O
hepatitis O
B O
surface O
antigen O
( O
HBsAg O
) O
and O
hepatitis B
B I
e I
antigen I
( O
HBeAg O
) O
positive O
mothers O
. O

Each O
rat O
was O
then O
injected O
with O
alfentanil O
( O
ALF B
, O
0 O
. O
5 O
mg O
/ O
kg O
sc O
) O
. O

ALF B
injection O
resulted O
in O
a O
marked O
increase O
in O
hindlimb O
EMG O
activity O
in O
the O
L O
- O
MED O
treatment O
group O
which O
was O
indistinguishable O
from O
that O
seen O
in O
animals O
treated O
with O
saline O
. O

These O
findings O
are O
consistent O
with O
the O
postulated O
mechanism O
for O
this O
unusual O
syndrome O
: O
acute O
diffuse O
crystallization O
of O
uric B
acid I
in O
renal O
tubules O
. O

GABA O
involvement O
in O
naloxone O
induced O
reversal O
of O
respiratory O
paralysis O
produced O
by O
thiopental B
. O

In O
this O
study O
naloxone O
reversed O
respiratory O
paralysis O
induced O
by O
thiopental B
in O
rats O
. O

25 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
thiopental B
produced O
anesthesia O
without O
altering O
respiratory O
rate O
, O
increased O
GABA O
, O
decreased O
glutamate O
, O
and O
had O
no O
effect O
on O
aspartate O
or O
glycine O
levels O
compared O
to O
controls O
in O
rat O
cortex O
and O
brain O
stem O
. O

Pretreatment O
of O
rats O
with O
thiosemicarbazide O
for O
30 O
minutes O
abolished O
the O
anesthetic O
action O
as O
well O
as O
the O
respiratory O
depressant O
action O
of O
thiopental B
. O

50 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
thiopental B
produced O
respiratory O
arrest O
with O
further O
increase O
in O
GABA O
and O
decrease O
in O
glutamate O
again O
in O
cortex O
and O
brain O
stem O
without O
affecting O
any O
of O
the O
amino B
acids I
studied O
in O
four O
regions O
of O
rat O
brain O
. O

These O
data O
suggest O
naloxone O
reverses O
respiratory O
paralysis O
produced O
by O
thiopental B
and O
involves O
GABA O
in O
its O
action O
. O

Glycopyrronium B
requirements O
for O
antagonism O
of O
the O
muscarinic O
side O
effects O
of O
edrophonium O
. O

We O
have O
compared O
, O
in O
60 O
adult O
patients O
, O
the O
cardiovascular O
effects O
of O
glycopyrronium B
5 O
micrograms O
kg O
- O
1 O
and O
10 O
micrograms O
kg O
- O
1 O
given O
either O
simultaneously O
or O
1 O
min O
before O
edrophonium O
1 O
mg O
kg O
- O
1 O
. O

Use O
of O
glycopyrronium B
5 O
micrograms O
kg O
- O
1 O
provided O
greater O
cardiovascular O
stability O
and O
, O
given O
1 O
min O
before O
the O
edrophonium O
, O
was O
sufficient O
to O
minimize O
early O
, O
edrophonium O
- O
induced O
bradycardias O
. O

This O
low O
dose O
of O
glycopyrronium B
provided O
good O
control O
of O
oropharyngeal O
secretions O
. O

Antagonism O
of O
diazepam O
- O
induced O
sedative O
effects O
by O
Ro15 B
- I
1788 I
in O
patients O
after O
surgery O
under O
lumbar O
epidural O
block O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
Ro15 B
- I
1788 I
and O
a O
placebo O
in O
reversing O
diazepam O
- O
induced O
effects O
after O
surgery O
under O
epidural O
block O
, O
and O
to O
evaluate O
the O
local O
tolerance O
and O
general O
safety O
of O
Ro15 B
- I
1788 I
. O

Antagonism O
of O
diazepam O
- O
induced O
effects O
by O
Ro15 B
- I
1788 I
was O
investigated O
postoperatively O
in O
a O
double O
- O
blind O
placebo O
- O
controlled O
trial O
. O

The O
Ro15 B
- I
1788 I
group O
showed O
a O
significant O
improvement O
in O
the O
performance O
test O
up O
to O
120 O
min O
after O
administration O
of O
the O
drug O
. O

Chorea O
associated O
with O
oral B
contraception I
. O

The O
third O
patient O
had O
acute O
amphetamine O
- O
induced O
chorea O
after O
prolonged O
oral B
contraception I
. O

The O
potential O
modifying O
effect O
of O
retinyl O
acetate O
( O
RA B
) O
on O
butylated O
hydroxyanisole O
( O
BHA O
) O
- O
induced O
rat O
forestomach O
tumorigenesis O
was O
examined O
. O

Male O
F344 O
rats O
, O
5 O
weeks O
of O
age O
, O
were O
maintained O
on O
diet O
containing O
1 O
% O
or O
2 O
% O
BHA O
by O
weight O
and O
simultaneously O
on O
drinking O
water O
supplemented O
with O
RA B
at O
various O
concentrations O
( O
w O
/ O
v O
) O
for O
52 O
weeks O
. O

In O
groups O
given O
2 O
% O
BHA O
, O
although O
marked O
hyperplastic O
changes O
of O
the O
forestomach O
epithelium O
were O
observed O
in O
all O
animals O
, O
co O
- O
administration O
of O
0 O
. O
25 O
% O
RA B
significantly O
( O
P O
less O
than O
0 O
. O
05 O
) O
increased O
the O
incidence O
of O
forestomach O
tumors O
( O
squamous O
cell O
papilloma O
and O
carcinoma O
) O
to O
60 O
% O
( O
9 O
/ O
15 O
, O
2 O
rats O
with O
carcinoma O
) O
from O
15 O
% O
( O
3 O
/ O
20 O
, O
one O
rat O
with O
carcinoma O
) O
in O
the O
group O
given O
RA B
- O
free O
water O
. O

In O
rats O
given O
1 O
% O
BHA O
, O
RA B
co O
- O
administered O
at O
a O
dose O
of O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
0 O
. O
2 O
or O
0 O
. O
25 O
% O
showed O
a O
dose O
- O
dependent O
enhancing O
effect O
on O
the O
development O
of O
the O
BHA O
- O
induced O
epithelial O
hyperplasia O
. O

Tumors O
, O
all O
papillomas O
, O
were O
induced O
in O
3 O
rats O
( O
17 O
% O
) O
with O
0 O
. O
25 O
% O
RA B
and O
in O
one O
rat O
( O
10 O
% O
) O
with O
0 O
. O
05 O
% O
RA B
co O
- O
administration O
. O

RA B
alone O
did O
not O
induce O
hyperplastic O
changes O
in O
the O
forestomach O
. O

These O
findings O
indicate O
that O
RA B
acted O
as O
a O
co O
- O
carcinogen O
in O
the O
BHA O
forestomach O
carcinogenesis O
of O
the O
rat O
. O

Group O
II O
showed O
a O
better O
perioperative O
renal O
function O
as O
determined O
by O
serum O
blood O
urea B
nitrogen I
and O
serum O
creatinine O
levels O
. O

Production O
of O
autochthonous O
prostate O
cancer O
in O
Lobund O
- O
Wistar O
rats O
by O
treatments O
with O
N B
- I
nitroso I
- I
N I
- I
methylurea I
and O
testosterone O
. O

More O
than O
50 O
% O
of O
Lobund O
- O
Wistar O
( O
L O
- O
W O
) O
strain O
rats O
developed O
large O
, O
palpable O
prostate O
adenocarcinomas O
( O
PAs O
) O
following O
treatments O
with O
N B
- I
nitroso I
- I
N I
- I
methylurea I
( O
CAS O
: O
684 O
- O
93 O
- O
5 O
) O
and O
testosterone O
propionate O
[ O
( O
TP O
) O
CAS O
: O
57 O
- O
85 O
- O
2 O
] O
, O
and O
most O
of O
the O
tumor O
- O
bearing O
rats O
manifested O
metastatic O
lesions O
. O

The O
combined O
administration O
of O
CSA O
and O
various O
chemotherapeutic O
drugs O
with O
a O
nephrotoxic O
potential O
, O
such O
as O
gentamicin O
( O
at O
therapeutic O
doses O
) O
, O
amphothericin B
B I
and O
ketoconazole O
, O
which O
are O
frequently O
used O
in O
immunosuppressed O
patients O
, O
did O
not O
aggravate O
the O
CSA O
induced O
toxicity O
in O
the O
rat O
model O
. O

Bradycardia O
due O
to O
trihexyphenidyl B
hydrochloride I
. O

A O
chronic O
schizophrenic O
patient O
was O
treated O
with O
an O
anticholinergic O
drug O
, O
trihexyphenidyl B
hydrochloride I
. O

The O
present O
work O
has O
been O
planned O
in O
order O
to O
elucidate O
the O
effect O
of O
phenobarbital O
( O
PB B
: O
15 O
mg O
per O
rat O
of O
ingested O
dose O
) O
on O
carcinogenesis O
when O
it O
is O
administered O
simultaneously O
with O
diethylnitrosamine O
( O
DEN O
: O
10 O
mg O
/ O
kg O
/ O
day O
) O
. O

Wistar O
rats O
( O
180 O
g O
) O
were O
treated O
by O
DEN O
alone O
or O
by O
DEN O
+ O
PB B
during O
2 O
, O
4 O
and O
6 O
weeks O
according O
to O
our O
schedule O
for O
hepatocarcinogenesis O
. O

After O
the O
end O
of O
the O
treatment O
, O
the O
number O
and O
the O
size O
of O
induced O
PAS O
positive O
preneoplastic O
foci O
was O
significantly O
reduced O
when O
PB B
was O
given O
simultaneously O
with O
DEN O
for O
4 O
and O
6 O
weeks O
. O

The O
mitotic O
inhibition O
and O
the O
production O
of O
micronuclei O
normally O
observed O
after O
partial O
hepatectomy O
in O
DEN O
treated O
rats O
were O
also O
significantly O
decreased O
in O
DEN O
+ O
PB B
treated O
rats O
. O

When O
the O
treatment O
last O
only O
2 O
weeks O
, O
the O
presence O
of O
PB B
did O
not O
change O
significantly O
the O
last O
parameters O
. O

In O
DEN O
+ O
PB B
treated O
rats O
, O
the O
survival O
was O
prolonged O
and O
the O
tumor O
incidence O
decreased O
as O
compared O
with O
the O
results O
obtained O
by O
DEN O
alone O
. O

It O
is O
concluded O
that O
PB B
, O
which O
promotes O
carcinogenesis O
when O
administered O
after O
the O
DEN O
treatment O
, O
reduces O
the O
carcinogen O
effect O
when O
given O
simultaneously O
with O
DEN O
. O

Biochemical O
investigations O
are O
in O
progress O
to O
obtain O
more O
information O
about O
this O
' O
paradoxical O
' O
PB B
effect O
. O

Tri O
- O
ortho O
- O
tolyl O
phosphate O
( O
TOTP O
) O
, O
360 O
mg O
/ O
kg O
, O
po O
, O
and O
0 B
, I
0 I
' I
- I
diisopropyl I
phosphorofluoridate I
( O
DFP O
) O
, O
1 O
mg O
/ O
kg O
sc O
, O
were O
administered O
to O
adult O
White O
Leghorn O
chickens O
24 O
hr O
after O
they O
were O
placed O
on O
diets O
containing O
0 O
to O
300 O
ppm O
corticosterone O
. O

Neurotoxic O
esterase O
activities O
24 O
hr O
after O
TOTP O
or O
DFP O
were O
less O
than O
20 O
% O
of O
values O
measured O
in O
chickens O
not O
given O
organophosphorous B
compounds O
. O

Local O
anesthetics O
that O
are O
commonly O
used O
in O
ophthalmic O
surgery O
( O
0 O
. O
75 O
% O
bupivacaine B
hydrochloride I
, O
2 O
. O
0 O
% O
mepivacaine B
hydrochloride I
, O
and O
2 O
. O
0 O
% O
lidocaine B
hydrochloride I
plus O
1 O
: O
100 O
, O
000 O
epinephrine O
) O
were O
injected O
into O
the O
retrobulbar O
area O
of O
rat O
eyes O
. O

Transient O
hemiparesis O
: O
a O
rare O
manifestation O
of O
diphenylhydantoin B
toxicity O
. O

Among O
the O
common O
side O
effects O
of O
diphenylhydantoin B
( O
DPH B
) O
overdose O
, O
the O
most O
frequently O
encountered O
neurological O
signs O
are O
those O
of O
cerebellar O
dysfunction O
. O

Two O
patients O
are O
presented O
who O
suffered O
progressive O
hemiparesis O
due O
to O
DPH B
overdose O
. O

Both O
had O
brain O
surgery O
before O
DPH B
treatment O
. O

It O
is O
assumed O
that O
patients O
with O
some O
cerebral O
damage O
are O
liable O
to O
manifest O
DPH B
toxicity O
as O
focal O
neurological O
signs O
. O

Long O
- O
term O
administration O
of O
quinidine O
was O
associated O
with O
persistent O
elevation O
of O
serum O
concentrations O
of O
SGOT O
, O
lactic B
acid I
dehydrogenase O
, O
and O
alkaline O
phosphatase O
. O

A O
challenge O
dose O
of O
quinidine O
caused O
clinical O
symptoms O
and O
abrupt O
elevation O
of O
SGOT O
, O
alkaline O
phosphatase O
, O
and O
lactic B
acid I
dehydrogenase O
values O
. O

Appropriate O
treatment O
consists O
of O
discontinuation O
of O
heparin O
, O
and O
anticoagulation O
with O
sodium B
warfarin I
if O
necessary O
. O

Mean O
serum O
potassium O
level O
fell O
, O
and O
urea O
and O
uric B
acid I
levels O
rose O
, O
in O
men O
and O
women O
taking O
bendrofluazide O
. O

In O
the O
propranolol O
group O
, O
serum O
potassium O
and O
uric B
acid I
levels O
rose O
in O
both O
sexes O
, O
but O
the O
urea O
level O
rose O
significantly O
in O
women O
only O
. O

Both O
verapamil O
( O
10 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
and O
NH4Ac O
pretreatment O
enhanced O
morphine O
analgesia O
- O
and O
diazepam O
- O
induced O
muscular O
incoordination O
and O
antagonized O
amphetamine O
- O
induced O
motor O
activity O
, O
and O
neither O
verapamil O
nor O
NH4Ac O
affected O
the O
convulsant O
action O
of O
metrazol B
. O

Treatment O
of O
ifosfamide O
- O
induced O
urothelial O
toxicity O
by O
oral O
administration O
of O
sodium B
2 I
- I
mercaptoethane I
sulphonate I
( O
MESNA O
) O
to O
patients O
with O
inoperable O
lung O
cancer O
. O

The O
protective O
effect O
of O
oral O
administration O
of O
the O
thiol O
compound O
sodium B
2 I
- I
mercaptoethane I
sulphonate I
( O
MESNA O
) O
against O
urothelial O
toxicity O
induced O
by O
ifosfamide O
( O
IF B
) O
was O
tested O
in O
a O
group O
of O
45 O
patients O
with O
inoperable O
lung O
cancer O
under O
treatment O
with O
IF B
( O
2250 O
mg O
/ O
m2 O
on O
days O
2 O
- O
5 O
) O
as O
part O
of O
a O
polychemotherapy O
regimen O
repeated O
in O
a O
4 O
- O
week O
cycle O
. O

MESNA O
was O
given O
orally O
on O
the O
days O
of O
treatment O
with O
IF B
in O
3 O
doses O
of O
840 O
mg O
/ O
m2 O
, O
each O
administered O
at O
0 O
hr O
( O
= O
injection O
of O
IF B
) O
, O
4 O
hr O
and O
8 O
hr O
p O
. O
i O
. O

A O
further O
group O
of O
25 O
patients O
under O
polychemotherapy O
with O
IF B
were O
treated O
by O
conventional O
prophylactic O
measures O
( O
raised O
fluid O
intake O
and O
forced O
diuresis O
) O
. O

Our O
results O
support O
the O
view O
that O
MESNA O
, O
given O
orally O
in O
conjunction O
with O
combined O
cytostatic O
regimens O
which O
include O
IF B
, O
simplifies O
the O
treatment O
and O
provides O
optimum O
protection O
for O
the O
urinary O
epithelium O
. O

Effect O
of O
prostaglandin B
synthetase O
inhibitors O
on O
experimentally O
induced O
convulsions O
in O
rats O
. O

To O
investigate O
the O
relationship O
of O
prostaglandins O
( O
PGs B
) O
to O
seizure O
induction O
, O
the O
effects O
of O
six O
PG O
synthetase O
inhibitors O
on O
convulsions O
induced O
by O
flurothyl B
, O
picrotoxin O
, O
pentetrazol B
( O
PTZ O
) O
, O
electroshock O
or O
bicuculline O
were O
evaluated O
. O

Ibuprofen O
, O
sulindac O
, O
mefenamic O
acid O
, O
and O
low O
dose O
meclofenamic O
acid O
increased O
the O
latency O
- O
to O
- O
onset O
in O
the O
flurothyl B
and O
/ O
or O
PTZ O
models O
; O
the O
electroshock O
, O
picrotoxin O
and O
bicuculline O
models O
were O
not O
significantly O
affected O
by O
any O
of O
the O
pretreatment O
agents O
. O

These O
results O
suggest O
that O
PGs B
are O
involved O
in O
the O
mechanism O
( O
s O
) O
underlying O
fluorthyl B
- O
and O
PTZ O
- O
induced O
convulsions O
, O
but O
not O
picrotoxin O
- O
, O
electroshock O
- O
, O
or O
bicuculline O
- O
induced O
convulsions O
. O

Effect O
of O
captopril O
on O
pre O
- O
existing O
and O
aminonucleoside B
- O
induced O
proteinuria O
in O
spontaneously O
hypertensive O
rats O
. O

Effect O
of O
calcium O
chloride O
on O
gross O
behavioural O
changes O
produced O
by O
carbachol O
and O
eserine B
in O
cats O
. O

The O
effect O
of O
calcium O
chloride O
injected O
into O
the O
cerebral O
ventricles O
of O
group O
- O
housed O
unanaesthetized O
cats O
upon O
vocalization O
( O
rage O
, O
hissing O
and O
snarling O
) O
, O
fighting O
( O
attack O
with O
paws O
and O
claws O
, O
defense O
with O
paws O
and O
claws O
and O
biting O
) O
, O
mydriasis O
, O
tremor O
and O
clonic O
- O
tonic O
convulsions O
produced O
by O
carbachol O
and O
eserine B
injected O
similarly O
was O
investigated O
. O

Calcium O
chloride O
depressed O
or O
almost O
completely O
abolished O
the O
vocalization O
and O
fighting O
due O
to O
carbachol O
and O
eserine B
. O

On O
the O
other O
hand O
, O
mydriasis O
, O
tremor O
and O
clonic O
- O
tonic O
convulsions O
evoked O
by O
carbachol O
and O
eserine B
were O
not O
significantly O
changed O
by O
calcium O
chloride O
. O

It O
is O
apparent O
that O
calcium O
chloride O
can O
" O
dissociate O
" O
vocalization O
and O
fighting O
from O
autonomic O
and O
motor O
phenomena O
such O
as O
mydriasis O
, O
tremor O
and O
clonic O
- O
tonic O
convulsions O
caused O
by O
carbachol O
and O
eserine B
. O

Calcium O
chloride O
inhibited O
the O
vocalization O
and O
fighting O
produced O
by O
carbachol O
and O
eserine B
most O
probably O
by O
a O
nonspecific O
stabilizing O
action O
on O
central O
muscarinic O
cholinoceptive O
sites O
. O

This O
study O
was O
undertaken O
to O
ascertain O
whether O
the O
alterations O
of O
plasma O
lipoproteins O
found O
in O
nephrotic O
syndrome O
induced O
by O
puromycin O
aminonucleoside O
were O
due O
to O
nephrotic O
syndrome O
per O
se O
, O
or O
, O
at O
least O
in O
part O
, O
to O
the O
aminonucleoside B
. O

The O
CD50 O
and O
LD50 O
, O
respectively O
, O
were O
57 O
. O
7 O
and O
58 O
. O
7 O
mg O
/ O
kg O
for O
bupivacaine O
, O
111 O
. O
0 O
and O
133 O
. O
1 O
mg O
/ O
kg O
for O
lidocaine O
, O
and O
243 O
. O
4 O
and O
266 O
. O
5 O
mg O
/ O
kg O
for O
chloroprocaine B
. O

When O
given O
intraperitoneally O
, O
bupivacaine O
thus O
was O
only O
about O
twice O
as O
toxic O
as O
lidocaine O
and O
four O
times O
as O
toxic O
as O
chloroprocaine B
. O

A O
CD50 O
dose O
of O
local O
anesthetic O
( O
causing O
convulsions O
in O
50 O
% O
of O
mice O
) O
was O
fatal O
in O
90 O
% O
of O
bupivacaine O
- O
induced O
seizures O
, O
in O
57 O
% O
of O
the O
chloroprocaine B
group O
, O
and O
in O
6 O
% O
of O
the O
lidocaine O
group O
. O

The O
cardiomyopathy O
( O
CM O
) O
produced O
by O
the O
anticancer O
drug O
doxorubicin O
( O
DXR B
) O
( O
Adriamycin O
) O
provides O
a O
unique O
opportunity O
to O
analyze O
dose O
- O
effect O
and O
structure O
- O
function O
relationships O
during O
development O
of O
myocardial O
disease O
. O

We O
measured O
the O
degree O
of O
morphologic O
damage O
by O
ultrastructural O
examination O
of O
endomyocardial O
biopsy O
and O
the O
degree O
of O
performance O
abnormally O
by O
right O
heart O
catheterization O
in O
patients O
receiving O
DXR B
. O

Morphologic O
damage O
was O
variable O
but O
was O
proportional O
to O
the O
total O
cumulative O
DXR B
dose O
between O
100 O
and O
600 O
mg O
/ O
m2 O
. O

In O
DXR B
- O
CM O
myocardial O
damage O
is O
proportional O
to O
the O
degree O
of O
cytotoxic O
insult O
( O
DXR B
dose O
) O
while O
myocardial O
function O
is O
preserved O
until O
a O
critical O
dose O
or O
degree O
of O
damage O
is O
reached O
, O
after O
which O
myocardial O
performance O
deteriorates O
rapidly O
. O

She O
had O
ovarian O
failure O
after O
abdominal O
irradiation O
and O
chemotherapy O
for O
Hodgkin O
disease O
, O
and O
received O
exogenous O
estrogens B
, O
a O
treatment O
implicated O
in O
the O
development O
of O
endometrial O
cancer O
in O
menopausal O
women O
. O

Young O
women O
on O
replacement O
estrogens B
for O
ovarian O
failure O
after O
cancer O
therapy O
may O
also O
have O
increased O
risk O
of O
endometrial O
carcinoma O
and O
should O
be O
examined O
periodically O
. O

Cyclosporin O
A O
( O
CsA O
; O
50 O
mg O
/ O
kg O
) O
and O
Fujimycine B
( O
FK506 O
; O
5 O
mg O
/ O
kg O
) O
, O
but O
not O
the O
related O
macrolide O
immunosuppressant O
rapamycin O
( O
5 O
mg O
/ O
kg O
) O
, O
caused O
a O
reduction O
of O
glomerular O
filtration O
rate O
, O
degenerative O
changes O
of O
proximal O
tubular O
epithelium O
, O
and O
hypertrophy O
of O
the O
juxtaglomerular O
apparatus O
in O
male O
Wistar O
rats O
when O
given O
for O
10 O
days O
. O

Time O
dependence O
of O
plasma O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides B
during O
incomplete O
cerebral O
ischemia O
in O
the O
rat O
. O

Plasma O
extracts O
were O
analyzed O
by O
a O
highly O
sensitive O
high O
- O
performance O
liquid O
chromatographic O
method O
for O
the O
direct O
determination O
of O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides B
. O

During O
ischemia O
, O
a O
time O
- O
dependent O
increase O
of O
plasma O
oxypurines O
and O
nucleosides B
was O
observed O
. O

Increased O
plasma O
malondialdehyde O
was O
also O
recorded O
in O
two O
other O
groups O
of O
animals O
subjected O
to O
the O
same O
experimental O
model O
, O
one O
receiving O
20 O
mg O
/ O
kg O
b O
. O
w O
. O
of O
the O
cyclooxygenase O
inhibitor O
acetylsalicylate B
intravenously O
immediately O
before O
ischemia O
, O
the O
other O
receiving O
650 O
micrograms O
/ O
kg O
b O
. O
w O
. O
of O
the O
hypotensive O
drug O
nitroprusside O
at O
a O
flow O
rate O
of O
103 O
microliters O
/ O
min O
intravenously O
during O
ischemia O
, O
although O
in O
this O
latter O
group O
malondialdehyde O
was O
significantly O
higher O
. O

The O
present O
data O
indicate O
that O
the O
determination O
of O
malondialdehyde O
, O
oxypurines O
, O
and O
nucleosides B
in O
peripheral O
blood O
, O
may O
be O
used O
to O
monitor O
the O
metabolic O
alterations O
of O
tissues O
occurring O
during O
ischemic O
phenomena O
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

In O
normal O
rats O
, O
2 O
/ O
6 O
rats O
given O
free O
doxorubicin O
( O
DX B
) O
( O
5 O
mg O
/ O
kg O
) O
died O
within O
one O
week O
, O
whereas O
all O
control O
animals O
and O
all O
rats O
having O
received O
free O
NP O
or O
DXNP O
survived O
. O

A O
3 O
times O
higher O
proteinuria O
appeared O
in O
animals O
treated O
with O
DXNP O
than O
in O
those O
treated O
with O
DX B
. O

Two O
hr O
post O
- O
injection O
, O
DXNP O
was O
2 O
. O
7 O
times O
more O
concentrated O
in O
kidneys O
than O
free O
DX B
( O
p O
< O
0 O
. O
025 O
) O
. O

In O
rats O
with O
immune O
experimental O
glomerulonephritis O
, O
5 O
/ O
6 O
rats O
given O
DX B
died O
within O
7 O
days O
, O
in O
contrast O
to O
animals O
treated O
by O
DXNP O
, O
NP O
, O
or O
untreated O
, O
which O
all O
survived O
. O

Proteinuria O
appeared O
in O
all O
series O
, O
but O
was O
2 O
- O
5 O
times O
more O
intense O
( O
p O
> O
0 O
. O
001 O
) O
and O
prolonged O
after O
doxorubicin O
treatment O
( O
400 O
- O
700 O
mg O
/ O
day O
) O
, O
without O
significant O
difference O
between O
DXNP O
and O
DX B
. O

These O
results O
demonstrate O
that O
, O
in O
these O
experimental O
conditions O
, O
DXNP O
killed O
less O
animals O
than O
free O
DX B
, O
despite O
of O
an O
enhanced O
renal O
toxicity O
of O
the O
former O
. O

Prostanoids B
may O
, O
via O
release O
of O
tachykinins O
, O
contribute O
to O
both O
urge O
and O
bladder O
hyperactivity O
seen O
in O
inflammatory O
conditions O
of O
the O
lower O
urinary O
tract O
. O

Laboratory O
variables O
of O
renal O
function O
[ O
serum O
creatinine O
, O
blood O
urea O
nitrogen O
( O
BUN B
) O
and O
electrolytes O
] O
were O
evaluated O
before O
initiation O
of O
therapy O
and O
every O
2 O
days O
, O
until O
termination O
of O
the O
study O
( O
a O
period O
of O
at O
least O
6 O
days O
) O
. O

BUN B
and O
creatinine O
increased O
by O
> O
50 O
% O
of O
baseline O
levels O
in O
54 O
and O
45 O
% O
of O
Group O
A O
patients O
, O
respectively O
, O
compared O
to O
only O
20 O
and O
10 O
% O
of O
Group O
B O
patients O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
mean O
increments O
in O
BUN B
, O
creatinine O
, O
and O
K O
were O
reduced O
by O
63 O
, O
80 O
, O
and O
42 O
% O
, O
respectively O
, O
in O
Group O
B O
patients O
compared O
to O
Group O
A O
. O
Response O
to O
treatment O
did O
not O
differ O
significantly O
between O
the O
2 O
groups O
. O

Dextromethorphan O
( O
DM B
) O
, O
the O
dextrorotatory O
isomer O
of O
3 O
- O
hydroxy O
- O
N O
- O
methylmorphinan O
, O
is O
the O
main O
ingredient O
in O
a O
number O
of O
widely O
available O
, O
over O
- O
the O
- O
counter O
antitussives O
. O

There O
have O
also O
been O
two O
reported O
fatalities O
from O
DM B
overdoses O
( O
Fleming O
1986 O
) O
. O

This O
report O
describes O
a O
case O
of O
cognitive O
deterioration O
resulting O
from O
prolonged O
use O
of O
DM B
. O

The O
serum O
vecuronium B
level O
measured O
in O
1 O
patient O
14 O
days O
after O
the O
drug O
had O
been O
discontinued O
was O
172 O
ng O
/ O
mL O
. O

The O
oxytocin O
should O
be O
given O
only O
in O
Ringers O
lactate O
or O
, O
alternately O
, O
in O
Ringers O
lactate O
and O
a O
5 O
per O
cent O
dextrose B
and O
water O
solutions O
. O

Moreover O
, O
KF17837 O
( O
0 O
. O
625 O
mg O
/ O
kg O
p O
. O
o O
. O
) O
potentiated O
the O
anticataleptic O
effects O
of O
a O
subthreshold O
dose O
of O
L B
- I
3 I
, I
4 I
- I
dihydroxyphenylalanine I
( O
L O
- O
DOPA O
; O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
plus O
benserazide O
( O
6 O
. O
25 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

However O
, O
yohimbine O
and O
meperidine B
reduced O
predominantly O
the O
dyskinetic O
movements O
. O

Five O
months O
after O
starting O
nifedipine O
( O
Adalat B
) O
, O
two O
patients O
developed O
photodistributed O
facial O
telangiectasia O
, O
which O
became O
more O
noticeable O
with O
time O
. O

In O
situ O
hybridization O
methods O
were O
used O
to O
determine O
if O
glutamic B
acid I
decarboxylase O
( O
GAD O
) O
mRNA O
- O
containing O
neurons O
within O
the O
hilus O
of O
the O
dentate O
gyrus O
are O
vulnerable O
to O
seizure O
- O
induced O
damage O
in O
a O
model O
of O
chronic O
seizures O
. O

Changes O
in O
peroxisomes O
in O
preneoplastic O
liver O
and O
hepatoma O
of O
mice O
induced O
by O
alpha B
- I
benzene I
hexachloride I
. O

Peroxisomes O
in O
hepatomas O
and O
hyperplastic O
preneoplastic O
liver O
lesions O
induced O
in O
mice O
by O
500 O
ppm O
alpha B
- I
benzene I
hexachloride I
were O
examined O
histochemically O
and O
electron O
microscopically O
. O

OBJECTIVE O
: O
To O
test O
the O
hypothesis O
that O
, O
in O
lifetime O
captopril O
- O
treated O
spontaneously O
hypertensive O
rats O
( O
SHR O
) O
, O
the O
sympathetic O
nervous O
system O
contributes O
importantly O
to O
the O
hypertensive O
effect O
of O
dietary B
sodium I
chloride I
supplementation O
. O

Intravenous O
infusion O
of O
the O
ganglionic O
blocker O
hexamethonium O
resulted O
in O
a O
rapid O
decline O
in O
MAP O
that O
eliminated O
the O
dietary B
sodium I
chloride I
- O
induced O
increase O
in O
MAP O
in O
both O
groups O
. O

Therefore O
, O
60 O
male O
rats O
were O
randomly O
assigned O
to O
receive O
daily O
injection O
of O
saline O
( O
C O
) O
, O
methylprednisolone O
( O
M B
) O
, O
or O
triamcinolone O
( O
T B
) O
80 O
mg O
/ O
kg O
/ O
d O
for O
5 O
d O
. O

Nutritional O
intake O
, O
measured O
daily O
in O
15 O
animals O
, O
showed O
a O
significant O
reduction O
of O
food O
intake O
in O
the O
steroid O
- O
treated O
groups O
( O
- O
50 O
and O
- O
79 O
% O
in O
M B
and O
T B
, O
respectively O
) O
. O

Maximal O
twitches O
of O
the O
diaphragm O
were O
lower O
in O
the O
C O
group O
( O
653 O
+ O
/ O
- O
174 O
g O
/ O
cm O
( O
2 O
) O
) O
than O
in O
the O
M B
group O
( O
837 O
+ O
/ O
- O
171 O
g O
/ O
cm O
( O
2 O
) O
; O
p O
< O
0 O
. O
05 O
) O
and O
the O
T B
group O
( O
765 O
+ O
/ O
- O
145 O
g O
/ O
cm O
( O
2 O
) O
, O
NS O
) O
. O

Half O
- O
relaxation O
time O
was O
prolonged O
in O
both O
steroid O
groups O
, O
and O
time O
to O
peak O
tension O
was O
longer O
with O
M B
, O
whereas O
tetanic O
tensions O
were O
similar O
. O

ATPase O
staining O
of O
the O
diaphragm O
, O
scalenus O
medius O
, O
and O
gastrocnemius O
showed O
type O
IIb O
fiber O
atrophy O
in O
the O
steroid O
groups O
and O
also O
diaphragmatic O
type O
IIa O
atrophy O
with O
T B
, O
whereas O
histologic O
examinations O
revealed O
a O
normal O
muscular O
pattern O
with O
absence O
of O
necrosis O
. O

Finally O
, O
a O
pair O
- O
fed O
( O
PF O
) O
study O
, O
performed O
in O
18 O
rats O
( O
C O
, O
T B
, O
and O
PF O
) O
, O
showed O
that O
muscle O
atrophy O
was O
considerably O
less O
pronounced O
in O
PF O
animals O
than O
in O
T B
- O
treated O
animals O
. O

Recently O
, O
we O
demonstrated O
the O
hepatoprotective O
effects O
of O
nicotinic B
acid I
amide I
, O
a O
selective O
inhibitor O
of O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
( O
PARP O
; O
EC O
2 O
. O
4 O
. O
2 O
. O
30 O
) O
on O
mice O
suffering O
from O
acetaminophen O
( O
AAP O
) O
- O
hepatitis O
, O
suggesting O
that O
the O
AAP O
- O
induced O
liver O
injury O
involves O
a O
step O
which O
depends O
on O
adenoribosylation O
. O

While O
AAP O
caused O
a O
117 O
- O
fold O
elevation O
of O
serum O
transaminase O
activities O
in O
mice O
kept O
on O
a O
standard O
laboratory O
diet O
, O
which O
was O
significantly O
exacerbated O
by O
ethanol O
and O
inhibited O
by O
nicotinic B
acid I
amide I
( O
NAA B
) O
, O
adverse O
effects O
were O
noted O
in O
animals O
fed O
a O
diet O
free O
of O
precursors O
of O
NAD O
. O

A O
further O
64 O
% O
reduction O
of O
hepatitis O
was O
observed O
, O
when O
NAA B
was O
given O
to O
ethanol O
/ O
AAP O
- O
mice O
. O

Our O
results O
provide O
evidence O
that O
the O
AAP O
- O
induced O
hepatitis O
and O
its O
exacerbation O
by O
ethanol O
can O
either O
be O
reduced O
by O
end O
- O
product O
inhibition O
of O
PARP O
by O
NAA B
or O
by O
dietary O
depletion O
of O
the O
enzyme O
' O
s O
substrate O
NAD O
. O

We O
see O
the O
main O
application O
of O
NAA B
as O
for O
the O
combinational O
use O
in O
pharmaceutical O
preparations O
of O
acetaminophen O
in O
order O
to O
avoid O
hepatic O
damage O
in O
patients O
treated O
with O
this O
widely O
used O
analgesic O
. O

This O
drug O
was O
initiated O
in O
association O
with O
paroxetine O
and O
dosulepine B
hydrochloride I
in O
a O
tetraparetic O
patient O
with O
chronic O
pain O
. O

Fifteen O
min O
later O
, O
animals O
received O
CaCl2 O
, O
NaHCO3 B
, O
or O
saline O
. O

RESULTS O
: O
NaHCO3 B
briefly O
( O
5 O
min O
) O
reversed O
hypotension O
and O
QRS O
prolongation O
. O

During O
the O
follow O
- O
up O
, O
3 O
patients O
( O
12 O
% O
) O
developed O
steroid O
- O
induced O
elevated O
intraocular O
pressure O
( O
IOP O
) O
that O
resolved O
after O
corticosteroid B
therapy O
was O
discontinued O
. O

Neutrophil O
superoxide O
and O
hydrogen B
peroxide I
production O
in O
patients O
with O
acute O
liver O
failure O
. O

Defects O
in O
superoxide O
and O
hydrogen B
peroxide I
production O
may O
be O
implicated O
in O
the O
high O
incidence O
of O
bacterial O
infections O
in O
patients O
with O
acute O
liver O
failure O
( O
ALF O
) O
. O

Superoxide O
and O
hydrogen B
peroxide I
production O
by O
ALF O
neutrophils O
stimulated O
with O
zymosan O
opsonized O
with O
ALF O
serum O
was O
significantly O
reduced O
compared O
with O
the O
control O
subjects O
( O
P O
< O
0 O
. O
01 O
) O
. O

Superoxide O
and O
hydrogen B
peroxide I
production O
in O
neutrophils O
stimulated O
with O
formyl O
- O
methionyl O
- O
leucyl O
- O
phenylalanine O
( O
fMLP O
) O
from O
a O
further O
18 O
ALF O
patients O
was O
unaffected O
compared O
with O
control O
neutrophils O
. O

A O
murine O
model O
of O
adenomyosis O
: O
the O
effects O
of O
hyperprolactinemia O
induced O
by O
fluoxetine B
hydrochloride I
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
on O
adenomyosis O
induction O
in O
Wistar O
albino O
rats O
. O

Several O
structurally O
related O
metabolites O
of O
progesterone O
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
20 I
- I
ones I
) O
and O
deoxycorticosterone O
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
21 I
- I
diol I
- I
20 I
- I
ones I
) O
and O
their O
3 O
beta O
- O
epimers O
were O
evaluated O
for O
protective O
activity O
against O
pilocarpine O
- O
, O
kainic O
acid O
- O
and O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
- O
induced O
seizures O
in O
mice O
. O

NS O
was O
induced O
by O
a O
single O
injection O
of O
puromycin B
amino I
- I
nucleoside I
( O
PAN O
) O
. O

Estrogens B
, O
which O
have O
been O
associated O
with O
several O
types O
of O
human O
and O
animal O
cancers O
, O
can O
induce O
tumor O
angiogenesis O
in O
the O
pituitary O
of O
Fischer O
344 O
rats O
. O

We O
therefore O
conducted O
the O
present O
acute O
dose O
- O
response O
study O
in O
four O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP O
) O
- O
exposed O
cynomolgus O
monkeys O
primed O
to O
exhibit O
levodopa O
- O
induced O
dyskinesias O
to O
evaluate O
the O
locomotor O
and O
dyskinetic O
effects O
on O
challenge O
with O
four O
doses O
( O
from O
0 O
. O
03 O
to O
1 O
. O
0 O
mg O
/ O
kg O
) O
of O
A O
- O
86929 O
( O
[ O
- O
] O
- O
[ O
5aR O
, O
11bS O
] O
- O
4 O
, O
5 O
, O
5a O
, O
6 O
, O

The O
pilocarpine O
( O
PILO B
) O
model O
of O
epilepsy O
is O
characterized O
by O
an O
acute O
period O
of O
status O
epilepticus O
followed O
by O
spontaneous O
recurrent O
seizures O
and O
related O
brain O
damage O
. O

PILO B
- O
injected O
animals O
exhibited O
NPY O
immunoreactivity O
in O
the O
region O
of O
the O
mossy O
fibre O
terminals O
, O
in O
the O
dentate O
gyrus O
inner O
molecular O
layer O
and O
, O
in O
a O
few O
cases O
, O
within O
presumed O
granule O
cells O
. O

In O
addition O
, O
PILO B
injected O
animals O
exhibited O
a O
reduction O
in O
the O
number O
of O
NPY O
- O
immunoreactive O
interneurons O
compared O
with O
controls O
. O

The O
results O
demonstrate O
that O
changes O
in O
NPY O
expression O
, O
including O
expression O
in O
the O
granule O
cells O
and O
mossy O
fibres O
and O
the O
loss O
of O
vulnerable O
NPY O
neurons O
, O
are O
present O
in O
the O
PILO B
model O
of O
TLE O
. O

It O
differs O
from O
erythromycin B
only O
in O
the O
methylation O
of O
the O
hydroxyl O
group O
at O
position O
6 O
. O

Although O
the O
side O
- O
effect O
profile O
of O
erythromycin B
is O
established O
, O
including O
gastroenteritis O
and O
interactions O
with O
other O
drugs O
subject O
to O
hepatic O
mixed O
- O
function O
oxidase O
metabolism O
, O
experience O
with O
the O
newer O
macrolides O
is O
still O
being O
recorded O
. O

Cardiotoxicity O
has O
been O
demonstrated O
after O
both O
intravenous O
and O
oral O
administration O
of O
erythromycin B
but O
has O
never O
been O
reported O
with O
the O
newer O
macrolides O
. O

Effect O
of O
glyceryl B
trinitrate I
on O
the O
sphincter O
of O
Oddi O
spasm O
evoked O
by O
prostigmine B
- O
morphine O
administration O
. O

OBJECTIVE O
: O
In O
this O
study O
the O
effect O
of O
glyceryl B
trinitrate I
on O
the O
prostigmine B
- O
morphine O
- O
induced O
sphincter O
of O
Oddi O
spasm O
was O
evaluated O
in O
nine O
female O
patients O
with O
sphincter O
of O
Oddi O
dyskinesia O
. O

METHOD O
: O
Sphincter O
of O
Oddi O
spasm O
was O
induced O
by O
prostigmine B
- O
morphine O
administration O
( O
0 O
. O
5 O
mg O
prostigmine B
intramuscularly O
and O
10 O
mg O
morphine O
subcutaneously O
) O
and O
visualized O
by O
quantitative O
hepatobiliary O
scintigraphy O
. O

The O
entire O
procedure O
was O
repeated O
during O
glyceryl B
trinitrate I
infusion O
( O
Nitrolingual B
1 O
microg O
/ O
kg O
/ O
min O
for O
120 O
min O
) O
. O

RESULTS O
: O
Prostigmine B
- O
morphine O
provocation O
caused O
significant O
increases O
in O
the O
time O
to O
peak O
activity O
( O
Tmax O
) O
over O
the O
hepatic O
hilum O
( O
HH O
: O
34 O
. O
33 O
+ O
/ O
- O
5 O
. O
05 O
vs O
. O
22 O
. O
77 O
+ O
/ O
- O
3 O
. O
26 O
) O
and O
the O
common O
bile O
duct O
( O
CBD O
: O
60 O
. O
44 O
+ O
/ O
- O
5 O
. O
99 O
vs O
. O
40 O
. O
0 O
+ O
/ O
- O
2 O
. O
88 O
) O
and O
in O
the O
half O
- O
time O
of O
excretion O
( O
T1 O
/ O
2 O
) O
over O
the O
liver O
parenchyma O
( O
LP O
: O
120 O
. O
04 O
+ O
/ O
- O
16 O
. O

Glyceryl B
trinitrate I
infusion O
completely O
normalized O
the O
prostigmine B
- O
morphine O
- O
induced O
alterations O
in O
these O
quantitative O
parameters O
( O
TmaX O
over O
the O
LP O
: O
11 O
. O
33 O
+ O
/ O
- O
1 O
. O
13 O
; O
over O
the O
HH O
: O
18 O
. O
88 O
+ O
/ O
- O
1 O
. O
48 O
; O
and O
over O
the O
CBD O
: O
36 O
. O
22 O
+ O
/ O
- O
1 O
. O
92 O
; O
and O
T1 O
/ O
2 O
over O
the O
LP O
: O
28 O
. O
21 O
+ O
/ O
- O
1 O
. O
83 O
; O
over O
the O
HH O
: O
33 O
. O
42 O
+ O
/ O
- O
3 O
. O
10 O
; O
and O
over O
the O
CBD O
: O
41 O
. O
66 O
+ O
/ O
- O
6 O
. O
33 O

) O
, O
suggesting O
an O
effective O
sphincter O
- O
relaxing O
effect O
of O
glyceryl B
trinitrate I
. O

CONCLUSION O
: O
These O
results O
provide O
the O
first O
evidence O
of O
the O
effectiveness O
of O
glyceryl B
trinitrate I
on O
the O
morphine O
- O
induced O
sphincter O
of O
Oddi O
spasm O
in O
humans O
. O

Since O
glyceryl B
trinitrate I
is O
able O
to O
overcome O
even O
the O
drastic O
effect O
of O
morphine O
, O
it O
might O
be O
of O
relevance O
in O
the O
treatment O
of O
sphincter O
of O
Oddi O
dyskinesia O
. O

The O
purpose O
of O
this O
randomized O
, O
double O
- O
blind O
, O
prospective O
study O
was O
to O
investigate O
whether O
intravenous O
( O
i O
. O
v O
. O
) O
administration O
of O
methylprednisolone O
( O
MP B
) O
prevents O
this O
complication O
. O

Sixty O
- O
five O
patients O
, O
34 O
women O
and O
31 O
men O
, O
ages O
36 O
to O
80 O
years O
, O
received O
either O
normal O
saline O
before O
and O
after O
TDI O
( O
group O
1 O
) O
, O
125 O
mg O
i O
. O
v O
. O
MP B
before O
and O
saline O
after O
TDI O
( O
group O
2 O
) O
, O
or O
125 O
mg O
i O
. O
v O
. O
MP B
before O
and O
after O
TDI O
( O
group O
3 O
) O
. O

These O
data O
demonstrate O
that O
administration O
of O
MP B
before O
and O
after O
TDI O
reduces O
the O
frequency O
and O
severity O
of O
the O
arthralgia O
- O
myalgia O
syndrome O
. O

We O
conclude O
that O
125 O
mg O
i O
. O
v O
. O
MP B
should O
be O
given O
routinely O
before O
and O
after O
TDI O
of O
iron O
dextran O
. O

Prolongation O
of O
QT O
interval O
, O
torsades O
de O
pointes O
, O
and O
sudden O
cardiac O
death O
have O
been O
reported O
after O
concomitant O
administration O
with O
erythromycin B
or O
azole O
antifungal O
agents O
, O
but O
not O
with O
other O
CYP3A4 O
inhibitors O
. O

BACKGROUND O
: O
The O
most O
striking O
of O
carboplatin O
' O
s O
advantages O
( O
CBDCA B
) O
over O
cisplatin O
( O
CDDP B
) O
is O
its O
markedly O
reduced O
rate O
of O
neurotoxic O
effects O
. O

However O
, O
the O
use O
of O
CBDCA B
higher O
- O
intensity O
schedules O
and O
the O
association O
with O
other O
neurotoxic O
drugs O
in O
polychemotherapy O
may O
cause O
some O
concern O
about O
its O
safety O
with O
respect O
to O
peripheral O
nervous O
system O
damage O
. O

MATERIALS O
AND O
METHODS O
: O
Two O
different O
schedules O
of O
CBDCA B
administration O
( O
10 O
mg O
/ O
kg O
and O
15 O
mg O
/ O
kg O
i O
. O
p O
. O
twice O
a O
week O
for O
nine O
times O
) O
were O
evaluated O
in O
Wistar O
rats O
. O

RESULTS O
: O
CBDCA B
administration O
induced O
dose O
- O
dependent O
peripheral O
neurotoxicity O
. O

The O
dorsal O
root O
ganglia O
sensory O
neurons O
and O
, O
to O
a O
lesser O
extent O
, O
satellite O
cells O
showed O
the O
same O
changes O
as O
those O
induced O
by O
CDDP B
, O
mainly O
affecting O
the O
nucleus O
and O
nucleolus O
of O
ganglionic O
sensory O
neurons O
. O

Moreover O
, O
significant O
amounts O
of O
platinum O
were O
detected O
in O
the O
dorsal O
root O
ganglia O
and O
kidney O
after O
CBDCA B
treatment O
. O

CONCLUSIONS O
: O
CBDCA B
is O
neurotoxic O
in O
our O
model O
, O
and O
the O
type O
of O
pathological O
changes O
it O
induces O
are O
so O
closely O
similar O
to O
those O
caused O
by O
CDDP B
that O
it O
is O
probable O
that O
neurotoxicity O
is O
induced O
in O
the O
two O
drugs O
by O
the O
same O
mechanism O
. O

This O
model O
can O
be O
used O
alone O
or O
in O
combination O
with O
other O
drugs O
to O
explore O
the O
effect O
of O
CBDCA B
on O
the O
peripheral O
nervous O
system O
. O

Acute O
renal O
failure O
subsequent O
to O
the O
administration O
of O
rifampicin B
. O

The O
patients O
had O
developed O
transient O
renal O
failure O
after O
the O
intermittent O
administration O
of O
rifampicin B
. O

Risk O
for O
valvular O
heart O
disease O
among O
users O
of O
fenfluramine B
and O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
use O
of O
medication O
. O

BACKGROUND O
: O
Because O
uncontrolled O
echocardiographic O
surveys O
suggested O
that O
up O
to O
30 O
% O
to O
38 O
% O
of O
users O
of O
fenfluramine B
and O
dexfenfluramine O
had O
valvular O
disease O
, O
these O
drugs O
were O
withdrawn O
from O
the O
market O
. O

OBJECTIVE O
: O
To O
determine O
the O
risk O
for O
new O
or O
worsening O
valvular O
abnormalities O
among O
users O
of O
fenfluramine B
or O
dexfenfluramine O
who O
underwent O
echocardiography O
before O
they O
began O
to O
take O
these O
medications O
. O

PATIENTS O
: O
46 O
patients O
who O
used O
fenfluramine B
or O
dexfenfluramine O
for O
14 O
days O
or O
more O
and O
had O
echocardiograms O
obtained O
before O
therapy O
. O

RESULTS O
: O
Two O
patients O
( O
4 O
. O
3 O
% O
[ O
95 O
% O
CI O
, O
0 O
. O
6 O
% O
to O
14 O
. O
8 O
% O
] O
) O
receiving O
fenfluramine B
- O
phentermine O
developed O
valvular O
heart O
disease O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
effect O
of O
dosage O
regimen O
( O
once O
- O
daily O
vs O
. O
twice O
- O
daily O
) O
of O
tobramicyn B
on O
steady O
- O
state O
serum O
concentrations O
and O
toxicity O
. O

